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7ABSTRACT
Chlamydia trachomatis is a common cause of sexually transmitted infections 
(STI). Most infections remain asymptomatic and repeated infections are common, 
ZKLFKFDQ OHDG WRSHOYLF LQÀDPPDWRU\GLVHDVH 3,'DQGVHULRXV UHSURGXFWLYH
complications. C. trachomatisFDQEHFODVVL¿HGLQWRGLɣHUHQWJHQRW\SHVEDVHGRQWKH
major outer membrane protein gene (ompA) encoding the major outer membrane 
protein (MOMP): genotypes D–K cause urogenital infections and genotypes L1–L3 
cause lymphogranuloma venereum (LGV). 
Changes in the epidemiology of C. trachomatis have had a direct impact on 
diagnostics. LGV infection outbreaks were reported in 2003 in Europe after decades 
among men who have sex with men (MSM). A new variant of C. trachomatis (nvCT) 
ZDVLGHQWL¿HGLQ6ZHGHQLQZLWKDODUJHGHOHWLRQLQWKHSODVPLGOHDGLQJWR
IDLOLQJGHWHFWLRQE\WZRQXFOHLFDFLGDPSOL¿FDWLRQWHVWV1$$7$QRWKHUYDULDQW 
(FI-nvCT) emerged in Finland in 2019 with a nucleotide substitution in the 23 
ULERVRPDO ULERQXFOHLFDFLG U51$ OLNHZLVHHYDGLQJGHWHFWLRQ2WKHUPLFUREHV
causing infections in the genitourinary tract, such as the human papillomavirus 
(HPV), herpes simplex virus (HSV), Mycoplasma genitalium and human 
herpesvirus 6 (HHV-6) may also contribute to the epidemiology of C. trachomatis. 
C. trachomatisSURPRWHVLWVVXUYLYDOLQVLGHWKHKRVWFHOOWKURXJKVHFUHWHGHɣHFWRU
SURWHLQV7KHWUDQVFULSWLRQDOH[SUHVVLRQRIWKHJHQHVHQFRGLQJWKHVHHɣHFWRUVKDV
mainly been studied using C. trachomatis reference strains propagated in cultured 
cells and not with currently circulating strains.
In this thesis, the C. trachomatis ompA genotype distribution in Finland was 
studied with ompAUHDOWLPHSRO\PHUDVHFKDLQUHDFWLRQ3&5DQGWKHRFFXUUHQFH
RI WKH6ZHGLVKQY&7ZDV LQYHVWLJDWHGZLWKQY&7 UHDOWLPH3&5 LQXURJHQLWDO
specimens. The prevalence of the LGV types in extragenital specimens in Finland was 
investigated with C. trachomatis polymorphic membrane protein H (pmpH) gene 
UHDOWLPH3&5DQGWKH/*9W\SHVZHUHIXUWKHUW\SHGZLWKompAUHDOWLPH3&5DQG
VHTXHQFLQJ7KHSUHYDOHQFHRI+69++9+39DQGM. genitalium in urogenital 
samples of C. trachomatis NAAT positive and negative young women in Finland 
ZDVDQDO\VHGZLWKUHDOWLPH3&5/RZSDVVDJHQXPEHUC. trachomatis clinical 
isolates originating from cervical swabs and reference strains were used to study the 
expression of C. trachomatis ompA, chlamydial protease-like activity factor (cpaf), 
translocated actin-recruiting phosphoprotein (tarp) and chlamydial cytotoxin (tox) 
genes in a cervical epithelial cell line during the chlamydial developmental cycle 
ZLWKUHDOWLPHUHYHUVHWUDQVFULSWDVH3&5573&5
8$%675$&7
The three most prevalent C. trachomatis genotypes in Finland were E, F, and G 
FRPSULVLQJRYHURIDOOWKHJHQRW\SHVLGHQWL¿HGLQWKHXURJHQLWDOVDPSOHV7KH
percentage of infections due to genotypes F and G increased slightly in 1987–2008, 
EXWRWKHUZLVHWKHSURSRUWLRQRIJHQRW\SHVKDVUHPDLQHGTXLWHVWDEOH LQ)LQODQG
during the last ten years. Overall, the proportion of genotypes in Finland is fairly 
similar compared to the other countries in Europe. The Swedish nvCT was rare 
in Finland, as only two specimens (0.4%) containing the variant plasmid were 
detected. Indeed, the nvCT has seldom been reported in countries outside Sweden.
A genotyping method for identifying LGV types was set up for a diagnostic 
laboratory using NAATs for the detection of C. trachomatis. Among the 
C. trachomatis positive extragenital samples, nine samples (8%) contained LGV 
types and one sample (1%) contained both non-LGV and LGV types. The LGV types 
were detected mainly in rectal swabs and were mostly of genotype L2b. Altogether 
QLQH/*9'1$SRVLWLYHSDWLHQWVZHUHLGHQWL¿HGDQGWKH\ZHUHDOO060DQGDOO
H[FHSWRQHZHUHKXPDQLPPXQRGH¿FLHQF\YLUXV+,9SRVLWLYH7KHGDWDVKRZ
that LGV infections among MSM also occur in Finland, which should be taken 
into account when considering the management of rectal C. trachomatis infections. 
7KHSUHYDOHQFHRI+39'1$ZDVVLJQL¿FDQWO\KLJKHUDPRQJWKHC. trachomatis 
positives than the negatives (66% vs. 25%). The prevalence of HSV (1.9% vs. 0%), 
HHV-6 (11% vs. 14%), and M. genitalium'1$YVZDVQRWVLJQL¿FDQWO\
GLɣHUHQWEHWZHHQWKHC. trachomatis positive and negative women. The prevalence 
of HSV, HHV-6, HPV, M. genitalium, and the C. trachomatis ompA genotypes 
GLGQRWVLJQL¿FDQWO\GLɣHUEHWZHHQWKRVHZKRFOHDUHGWKHC. trachomatis infection 
and those who did not. The test-of-cure (TOC) samples were often (13%) positive 
for C. trachomatis. The high prevalence of HPV DNA among the C. trachomatis 
positives suggests greater sexual activity and increased risk for sexually transmitted 
pathogens. The overall prevalence rates of HSV, HHV-6, HPV and M. genitalium 
were similar to those reported elsewhere. 
Dissimilarities were observed in the gene expression patterns between the low-
passage-number C. trachomatis clinical isolates and the reference strains. The 
expression of ompA and the peak of tox expression were observed earlier in the 
reference strains than in most of the clinical isolates. The expression of cpaf was 
high in the reference strains compared to the clinical isolates at the mid-phase 
of the developmental cycle. All the strains had a similar tarpH[SUHVVLRQSUR¿OH
Most clinical isolates showed slower growth kinetics compared to the reference 
strains. The use of low-passage-number C. trachomatis clinical isolates instead of 
UHIHUHQFHVWUDLQVLQWKHJHQHH[SUHVVLRQVWXGLHVPLJKWEHWWHUUHÀHFWWKHVLWXDWLRQ
during human infection. 
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Chlamydia trachomatis on yleinen sukupuoliteitse tarttuvia infektioita aiheuttava 
bakteeri. Suurin osa infektioista on oireettomia ja toistuvat infektiot ovat yleisiä, 
mikä voi johtaa sisäsynnytintulehdukseen ja vakaviin lisääntymisterveyden komp-
likaatioihin. C. trachomatis voidaan luokitella ulkomembraaniproteiinia (MOMP) 
koodaavan ompA -geenin perusteella eri genotyyppeihin: genotyypit D–K aiheut-
tavat urogenitaalialueen infektioita ja genotyypit L1–L3 aiheuttavat lymphogranu-
loma venereumia (LGV). 
C. trachomatis -bakteerin epidemiologiassa on tapahtunut muutoksia, joilla 
on ollut suoria vaikutuksia diagnostiikkaan. Vuonna 2003 Euroopassa havaittiin 
vuosikymmenten jälkeen LGV-infektioita miehillä, joilla oli ollut seksiä miesten 
NDQVVD5XRWVLVVDWXQQLVWHWWLLQYXRQQDXXVLC. trachomatis -variantti (nvCT), 
jonka plasmidissa oleva deleetio johti sen tunnistamisen epäonnistumiseen kah-
della nukleiinihapon monistustestillä. Vastaavasti Suomessa todettiin vuonna 2019 
C. trachomatis -variantti (FI-nvCT), jonka 23S ribosomaalisessa ribonukleiiniha-
SRVVDU51$ROHYDQQXNOHRWLGLVXEVWLWXXWLRQWDNLDYDULDQWWLMlLO|\W\PlWWl\KGHOOl
QXNOHLLQLKDSRQPRQLVWXVWHVWLOOl0\|VPXLOODXURJHQLWDDOLDOXHHQLQIHNWLRLWDDLKH-
uttavilla mikrobeilla, kuten ihmisen papilloomaviruksella (HPV), herpes simplex 
-viruksella (HSV), Mycoplasma genitalium -bakteerilla tai ihmisen herpesvirus 
6:lla (HHV-6) voi olla vaikutusta C. trachomatis -bakteerin epidemiologiaan. 
C. trachomatis edesauttaa selviytymistään isäntäsolun sisällä tuottamiensa efekto-
riproteiinien avulla. Näitä efektoriproteiineja koodaavien geenien ekspressiota on 
tutkittu pääasiassa soluviljelmissä kasvatettujen C. trachomatis -referenssikantojen 
DYXOODHLNlDMDQNRKWDLVLOODYlHVW|VVlNLHUWlYLOOlNDQQRLOOD
7lVVlYlLW|VNLUMDW\|VVlPllULWHWWLLQC. trachomatis ompA-genotyyppijakauma 
Suomessa urogenitaalialueen näytteissä reaaliaikaisella ompA-geeniä tunnistavalla 
SRO\PHUDDVLNHWMXUHDNWLR3&5WHVWLOOl5XRWVDODLVHQQY&7QHVLLQW\Y\\WWlXURJHQL-
WDDOLDOXHHQQl\WWHLVVlWXWNLWWLLQUHDDOLDLNDLVHOODQY&73&5OOl/*9W\\SSLHQHVLLQW\-
vyyttä nielun ja peräsuolen limakalvonäytteissä Suomessa tutkittiin reaaliaikaisella 
C. trachomatis EDNWHHULQSRO\PRU¿VWDPHPEUDDQLSURWHLLQL+pmpH) -geeniä 
WXQQLVWDYDOOD3&5OOlMD/*9W\\SLWWXQQLVWHWWLLQWDUNHPPLQUHDDOLDLNDLVHOODompA-
3&5OOlMDVHNYHQVRLQQLOOD+69Q++9Q+39QMDM. genitalium -bakteerin 
esiintyvyyttä C. trachomatis -positiivisten ja -negatiivisten nuorten naisten uroge-
QLWDDOLDOXHHQQl\WWHLVVl6XRPHVVDWXWNLWWLLQUHDDOLDLNDLVHOOD3&5OOlC. trachomatis 
-bakteerin proteaasia (cpaf), fosfoproteiinia (tarp) ja sytotoksiinia (tox) koodaavien 
geenien sekä ompA -geenin ekspressio bakteerin elinkierron aikana analysoitiin 
UHDDOLDLNDLVHOODNllQWHLVNRSLRLQWL3&5OOl573&5NRKGXQNDXODQHSLWHHOLVROXOLQ-
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jassa kohdunkaulan limakalvonäytteistä peräisin olevilla kliinisillä C. trachomatis 
-kannoilla ja -referenssikannoilla.
Kolme yleisintä C. trachomatis -genotyyppiä Suomessa olivat E, F ja G, ja niiden 
osuus oli yli 70% kaikista urogenitaalialueen näytteistä tunnistetuista genotyypeis-
tä. Genotyyppien F ja G aiheuttamien infektioiden prosenttiosuus suureni hiukan 
vuosina 1987–2008. Viimeisen kymmenen vuoden aikana genotyyppijakauma on 
pysynyt melko vakaana ja se on Suomessa melko samanlainen kuin muissa Eu-
URRSDQPDLVVD5XRWVDODLQHQYDULDQWWLROLKDUYLQDLQHQ6XRPHVVDVLOOlYDLQNDN-
VLQl\WHWWlVLVlOVLYDULDQWWLSODVPLGLQ7lWlYDULDQWWLDRQO|\GHWW\KDUYRLQ
5XRWVLQXONRSXROHOWD
7lVVlW\|VVlSHUXVWHWWLLQGLDJQRVWLVHQODERUDWRULRQNl\WW||QVRYHOWXYDW\\SLW\V-
menetelmä LGV-tyyppien tunnistamiseksi. C. trachomatis -positiivisista nielun ja 
peräsuolen limakalvonäytteistä yhdeksän näytettä (8%) sisälsi LGV-tyypin ja yksi 
näyte (1%) sekä LGV- että non-LGV-tyypin. LGV-tyypit havaittiin enimmäkseen 
peräsuolesta otetuista näytteistä ja ne olivat pääasiassa genotyyppiä L2b. LGV-
DNA-positiivisia potilaita tunnistettiin yhdeksän, joista kaikilla oli ollut miesten 
välistä seksiä ja kaikki paitsi yksi olivat HIV-positiivisia. Tulokset osoittavat, että 
/*9LQIHNWLRLWDHVLLQW\\P\|V6XRPHVVDOlKLQQlPLHVWHQYlOLVHVVlVHNVLVVlPLNl
tulee ottaa huomioon C. trachomatis -bakteerin aiheuttamien peräsuolitulehdusten 
diagnostiikassa ja hoidossa.
HPV-DNA:n esiintyvyys oli merkitsevästi korkeampi C. trachomatis -positiivis-
ten kuin -negatiivisten joukossa (66% vs. 25%). HSV- (1,9% vs. 0%), HHV-6- (11% 
vs. 14%) ja M. genitalium-DNA:n (4,5% vs. 1,9%) esiintyvyys ei ollut merkitsevästi 
erilainen C. trachomatis -positiivisten ja -negatiivisten naisten välillä. HSV:n, HHV-
6:n, HPV:n, M. genitalium -bakteerin ja C. trachomatis ompA-genotyyppien esiin-
tyvyys ei eronnut merkittävästi niiden välillä, joiden C. trachomatis -infektio parani 
ja joiden C. trachomatis -infektio ei parantunut. Jälkitarkastusnäytteet olivat usein 
(13%) C. trachomatis -positiivisia. HPV-DNA:n korkea esiintyvyys C. trachomatis 
-positiivisilla viittaa suurempaan seksuaaliseen aktiivisuuteen ja lisääntyneeseen 
riskiin saada sukupuoliteitse tarttuva infektio. HSV:n, HHV-6:n, HPV:n ja M. ge-
nitalium -bakteerin esiintyvyys oli samankaltainen kuin muissa maissa raportoitu.
Kliinisten C. trachomatisNDQWRMHQMDUHIHUHQVVLNDQWRMHQJHHQLHNVSUHVVLRSUR¿L-
lien välillä havaittiin eroja. C. trachomatis ompA-geenin ekspressio alkoi aikaisem-
min ja tox-geenin ekspression huippu havaittiin aikaisemmin referenssikannoilla 
kuin useimmilla kliinisillä kannoilla. C. trachomatis cpaf-geenin ekspressiotaso oli 
referenssikannoilla korkeampi C. trachomatis -bakteerin elinkierron keskivaiheessa 
verrattuna kliinisiin kantoihin. Kaikilla kannoilla oli samankaltainen tarp-geenin 
HNVSUHVVLRSUR¿LOL/lKHVNDLNNLHQNOLLQLVWHQNDQWRMHQNDVYXROLKLWDDPSDDNXLQUH-
ferenssikantojen. Kliinisten C. trachomatis NDQWRMHQNl\WW|JHHQLHNVSUHVVLRWXWNL-
muksissa referenssikantojen sijasta voisi paremmin kuvastaa tilannetta ihmisen 
tartunnan aikana.
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ABBREVIATIONS
ATCC  American Type Culture Collection
ATP  Adenosine triphosphate
BLAST  Basic local alignment search tool
bp  Base pairs
CD  Constant domain
cDNA  Complementary DNA
cpaf  Chlamydial protease-like activity factor gene
CPAF  Chlamydial protease-like activity factor
&5%  Chlamydia-related bacteria
DNA  Deoxyribonucleic acid
EB  Elementary body
ECDC  European Centre for Disease Prevention and Control
EIA  Enzyme immunoassay
ENA  European Nucleotide Archive
FDA  Food and Drug Administration
FI-nvCT Finnish new variant of Chlamydia trachomatis
FVU  First-void urine
*(  *HQRPHHTXLYDOHQW
HHV-6  Human herpesvirus 6
+,9  +XPDQLPPXQRGH¿FLHQF\YLUXV
hpi  Hours post infection
HPV  Human papillomavirus
HSP  Heat shock protein
HSV  Herpes simplex virus
IFN-J  Interferon-gamma
Ig  Immunoglobulin
kb  Kilo base pairs
LPS  Lipopolysaccharide
LGV  Lymphogranuloma venereum
Mb  Mega base pairs
0,)  0LFURLPPXQRÀXRUHVFHQFH
0/67  0XOWLORFXVVHTXHQFHW\SLQJ
MLVA  Multi locus variable number tandem repeat analysis
MOMP  Major outer membrane protein
P51$  0HVVHQJHUULERQXFOHLFDFLG
MSM  Men who have sex with men
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1$$7  1XFOHLFDFLGDPSOL¿FDWLRQWHVW
NCBI  National Center for Biotechnology Information
NF-ǉB  Nuclear factor-ǉB
1,'5  7KH1DWLRQDO,QIHFWLRXV'LVHDVH5HJLVWHU
nvCT  New variant of Chlamydia trachomatis
ompA  Major outer membrane protein gene
25)  2SHQUHDGLQJIUDPH
3&5  3RO\PHUDVHFKDLQUHDFWLRQ
Pgp  Plasmid glycoprotein
3,'  3HOYLFLQÀDPPDWRU\GLVHDVH
pmp  Polymorphic membrane protein gene 
Pmp  Polymorphic membrane protein
POCT  Point-of-care test
355  3DWWHUQUHFRJQLWLRQUHFHSWRU
5%  5HWLFXODWHERG\
5)/3  5HVWULFWLRQIUDJPHQWOHQJWKSRO\PRUSKLVP
51$  5LERQXFOHLFDFLG
U51$  5LERVRPDOULERQXFOHLFDFLG
573&5 5HYHUVHWUDQVFULSWDVH3&5
6'$  6WUDQGGLVSODFHPHQWDPSOL¿FDWLRQ
SNP  Single nucleotide polymorphism
STI  Sexually transmitted infection
T3SS  Type III secretion system
tarp  Translocated actin-recruiting phosphoprotein gene
Tarp  Translocated actin-recruiting phosphoprotein
TFI  Tubal factor infertility
70$  7UDQVFULSWLRQPHGLDWHGDPSOL¿FDWLRQ
TOC  Test-of-cure
tox  Chlamydial cytotoxin gene
VD  Variable domain
:*6  :KROHJHQRPHVHTXHQFLQJ
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1. INTRODUCTION
The global health burden due to sexually transmitted infections (STI) is enormous 
(Collaborators 2016). It is estimated that one million infections involving the 
four curable sexually transmitted diseases chlamydia, gonorrhoea, syphilis and 
WULFKRPRQLDVLVDUHDFTXLUHGHDFKGD\5RZOH\HWDOChlamydia trachomatis 
LVWKHPRVWFRPPRQEDFWHULDOFDXVHRI67,VDQGLWDɣHFWVHVSHFLDOO\\RXQJDGXOWV
5RZOH\HWDO0RVWC. trachomatis infections are asymptomatic and repeated 
LQIHFWLRQVDUHFRPPRQZKLFKFDQOHDGWRVHULRXVVHTXHODHRILQIHFWLRQVVXFKDV
SHOYLF LQÀDPPDWRU\GLVHDVH3,'HFWRSLFSUHJQDQF\DQGWXEDOIDFWRU LQIHUWLOLW\
(TFI) (Wiesenfeld 2017). 
C. trachomatisFDQEHFODVVL¿HGLQWRGLɣHUHQWJHQRW\SHVEDVHGRQWKHPDMRU
outer membrane protein gene (ompA) encoding the major outer membrane protein 
(MOMP) (Morré et al. 1998): genotypes D–K cause urogenital infections and 
genotypes L1–L3 cause lymphogranuloma venereum (LGV). LGV is an invasive 
STI resulting in severe inguinal lymphadenopathy (Mabey & Peeling 2002). It was 
previously encountered mainly in Africa, Asia and South America, but in 2003 
several outbreaks of infection caused by C. trachomatis LGV types were observed 
among men who have sex with men (MSM) in the Western countries (Martin-
,JXDFHOHWDO7KHGLVHDVHSUHVHQWHGGLɣHUHQWFOLQLFDOV\PSWRPVWRWKRVH
previously described, as a mild or asymptomatic proctitis was mainly observed 
DPRQJWKHSDWLHQWV7KHVH/*9SRVLWLYHSDWLHQWVZHUHDOVRDɣHFWHGE\KLJKUDWHV
RIRWKHU67,VVXFKDVWKHKXPDQLPPXQRGH¿FLHQF\YLUXV+,9
Antibiotic resistance among C. trachomatis strains is extremely rare (Sandoz 
	5RFNH\DQGWKHVHSDWKRJHQVKDYHXWLOLVHGRWKHUVWUDWHJLHVIRUVSUHDGLQJ
In 2006, the Swedish new variant of C. trachomatis (nvCT) emerged harbouring 
D ODUJHGHOHWLRQ LQWKHFKODP\GLDOFU\SWLFSODVPLG5LSD	1LOVVRQ7KLV
GHOHWLRQVLWHUHVLGHGLQWKHWDUJHWVHTXHQFHVRIWZRPDMRUQXFOHLFDFLGDPSOL¿FDWLRQ
test (NAAT) manufacturers, which led to failing detection of several thousand 
C. trachomatis cases in Sweden (Jurstrand et al. 2013). 
C. trachomatis co-infections with other sexually transmitted microbes are 
H[WUHPHO\FRPPRQEXWWKHLQWHUDFWLRQDQGFRQVHTXHQFHVRIWKHVHFRLQIHFWLRQVKDYH
only been partially explored. C. trachomatis is a known co-factor in the development 
of cervical cancer together with the human papillomavirus (HPV) (Castellsagué 
et al. 2014; Lehtinen et al. 2011). In addition, herpesviruses have been shown to 
interact with C. trachomatis by promoting persistence of C. trachomatis (Deka et 
al. 2006; Prusty et al. 2012). The data on the local and global prevalence of sexually 
transmitted microbes are important in planning public health interventions. 
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Transcriptional gene expression analysis has revealed new aspects of the biology 
of C. trachomatis infections (Belland et al. 2003; Nicholson et al. 2003). However, 
these studies have often used reference strains, which might be adapted to growing in 
cultured cell lines used in laboratories. Molecular characterization of C. trachomatis 
using low-passage-number isolates might better represent the biological properties 
of the strains currently causing infections. As gene expression studies are usually 
performed in vitro using cultured cell lines, the gene expression of C. trachomatis 
during human genital infection in vivo remains an understudied area in Chlamydia 
research.
This thesis studies the Finnish C. trachomatis ompA genotype distribution in 
urogenital samples and investigates whether the genotypes L1–L3 causing LGV also 
occur in Finland by examining extragenital samples. It also studies whether the 
Swedish nvCT has spread to Finland, and explores the prevalence of other sexually 
transmitted pathogens including herpes simplex virus (HSV), human herpesvirus 6 
(HHV-6), HPV and Mycoplasma genitalium in urogenital specimens. In addition, 
selected low-passage-number C. trachomatis clinical isolates from cervical samples 
are characterised for transcriptional expression of genes encoding important 
FKODP\GLDOHɣHFWRUSURWHLQV
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2. REVIEW OF THE LITERATURE
2.1 CHLAMYDIALES
Chlamydia are small (0.2–1.5 Pm) obligate intracellular Gram-negative bacteria of 
the family Chlamydiaceae, order Chlamydiales, phylum ChlamydiaeZLWKDXQLTXH
two-phase developmental cycle (Whitman 2015). Chlamydia was discovered in 1907 
when the intracytoplasmic inclusions in conjunctival scrapings from orangutans 
were described using Giemsa staining (Halberstaedter & von Prowazek 1907). In 
WKH¿UVWJHQLWDOLVRODWHRIC. trachomatis was recovered from the cervix of a 
ZRPDQZLWK3,'XVLQJWKH\RONVDFFXOWXUHWHFKQLTXH-RQHVHWDO
The family Chlamydiaceae includes one genus, Chlamydia, which contains 
eleven established species: C. abortus, C. avium, C. caviae, C. felis, C. gallinacea, 
C. muridarum, C. pecorum, C. pneumoniae, C. psittaci, C. suis and C. trachomatis 
(Table 1) (Sachse et al. 2015). The division of the family Chlamydiaceae into 
two genera, Chlamydia and Chlamydophila, has been proposed (Everett et al. 
1999), but this separation has later been proved invalid based on 16S ribosomal 
ULERQXFOHLFDFLGU51$VHTXHQFHDQGJHQRPLFVLPLODULW\RIWKHGLɣHUHQWChlamydia 
species (Sachse et al. 2015). C. trachomatis and C. pneumoniae are the two major 
species that cause infections in humans. C. pneumoniae is a common cause of 
UHVSLUDWRU\WUDFWLQIHFWLRQDQGFRPPXQLW\DFTXLUHGSQHXPRQLD5RXOLVHWDO 
A C. pneumoniae infection has also been suggested to be associated with several 
chronic conditions such as asthma and atherosclerosis. C. psittaci causes psittacosis 
in birds and can be zoonotically transmitted to humans, causing respiratory tract 
infection and pneumonia (Knittler et al. 2014). 
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Table 1. Characteristics of the eleven different species in the genus Chlamydia.  
Modified from Sachse et al. (2015).
Species Natural host Site of infection
Genome 
size (Mb)
Predicted 
proteins
C. abortus sheep, goat genital, respiratory 1.14 932
C. avium pigeon, parrots respiratory 1.05 940
C. caviae guinea pig ocular, genital 1.18 1005
C. felis cat ocular, respiratory 1.17 1013
C. gallinacea chicken respiratory 1.04 907
C. muridarum rodents gastrointestinal 1.08 911
C. pecorum cattle, koala gastrointestinal, 
respiratory, urogenital
1.11 988
C. pneumoniae human, horse, 
koala
respiratory, 
cardiovascular
1.23 1113
C. psittaci birds respiratory 1.17 975
C. suis swine gastrointestinal, genital 1.08 931
C. trachomatisa human genital, ocular 1.04 894
Mb, mega base pairs; a C. trachomatis D/UW-3/CX (Stephens et al. 1998).
The order Chlamydiales has recently expanded to include at least seven 
additional families: Clavichlamydiaceae, Criblamydiaceae, Parachlamydiaceae, 
Piscichlamydiaceae, Rhabdochlamydiaceae, Simkaniaceae and Waddliaceae 
(Whitman 2015). These ChlamydiaUHODWHGEDFWHULD&5%VKDUHWKHLQWUDFHOOXODU
lifestyle and developmental cycle of the Chlamydia species and have been isolated 
from a wide variety of hosts. It was estimated that the Parachlamydiaceae and 
Chlamydiaceae families diverged from the last common obligate intracellular 
DQFHVWRUPRUHWKDQPLOOLRQ\HDUVDJR*UHXE	5DRXOW7KHJHQRPHV
RI&5%DUHURXJKO\WZRWRWKUHHWLPHVODUJHUWKDQWKHJHQRPHVRIWKHChlamydia 
species (Taylor-Brown et al. 2015). It seems that the Chlamydia species have gone 
through massive genome reduction during co-evolution with their eukaryotic hosts 
6WHSKHQVHWDO7KHSDWKRJHQLFLW\RIGLɣHUHQW&5%WRKXPDQVLVRQO\SDUWLDOO\
characterised. Simkania negevensis and Parachlamydia spp. have been associated 
with respiratory infections and Waddlia chondrophila with miscarriage and other 
adverse pregnancy outcomes (Taylor-Brown et al. 2015). 
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2.2  EPIDEMIOLOGY OF CHLAMYDIA TRACHOMATIS
The C. trachomatis urogenital infection is the most common sexually transmitted 
EDFWHULDOLQIHFWLRQZLWKDQHVWLPDWHGPLOOLRQFDVHVRFFXUULQJDQQXDOO\5RZOH\
et al. 2019). In 2017, 26 European countries reported more than 400 000 
C. trachomatis cases to the European Centre for Disease Prevention and Control 
(ECDC) (ECDC 2019a). In 2016, the global prevalence estimate for C. trachomatis 
ZDVLQZRPHQDQGLQPHQ5RZOH\HWDO7KHHVWLPDWHGSUHYDOHQFH
in 2016 was similar to the one reported in 2012, which shows that C. trachomatis 
infections are persistently endemic worldwide (Newman et al. 2015). In Finland, a 
similar prevalence of 3.5% was reported among 18-year-old women participating 
in a C. trachomatis screening trial (Lehtinen et al. 2018).
7KH QRWL¿FDWLRQ UDWH IRU WKH  (XURSHDQ FRXQWULHV ZLWK FRPSUHKHQVLYH
surveillance systems was 146 C. trachomatis cases per 100 000 population in 
2017 (ECDC 2019a). In Finland, the incidence of C. trachomatis was 270 cases 
per 100 000 inhabitants in 2018. In the other Nordic countries, the incidence 
of C. trachomatis was 337/100 000 in Sweden, 478/100 000 in Norway and 
573/100 000 in Denmark in 2017. All the Nordic countries, including Finland, use 
ZLGHVSUHDGRSSRUWXQLVWLFVFUHHQLQJ&RPSDULQJWKHLQFLGHQFHRUQRWL¿FDWLRQUDWHV
EHWZHHQFRXQWULHVLVFKDOOHQJLQJEHFDXVHRIWKHGLɣHUHQFHVLQVFUHHQLQJDSSURDFKHV
GLDJQRVWLFPHWKRGVFDVH¿QGLQJDQGUHSRUWLQJ
In Finland, C. trachomatisLQIHFWLRQVKDYHEHHQQRWL¿HGE\ODERUDWRULHVWRWKH
1DWLRQDO,QIHFWLRXV'LVHDVH5HJLVWHU1,'5PDLQWDLQHGE\WKH)LQQLVK,QVWLWXWHIRU
+HDOWKDQG:HOIDUHVLQFH7KHDQQXDOQXPEHURIQRWL¿HGFDVHVKDVEHHQVWDEOH
DQGKDVUHPDLQHGDURXQG±IRUWKHODVWWHQ\HDUV)LJXUH1,'5
,QWKHUHZHUHQRWL¿HGC. trachomatis cases in Finland. Most 
infections were reported among young women of Finnish origin: 58% were women, 
79% were 15–29 years old and 91% were Finnish. On an average, C. trachomatis 
infections occur at a younger age in women compared to men: two-thirds of the 
women were infected under 25 years of age, while one-third of the men were infected 
under 25 years of age. 
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Figure 1. The number of C. trachomatis cases in men and women notified by laboratories in Finland in 
2009–2018. (NIDR 2019).
2.3 C. TRACHOMATIS INFECTIONS
2.3.1 UROGENITAL INFECTION 
The analysis of the MOMP of C. trachomatis and the ompA gene encoding MOMP 
KDV OHGWRWKH LGHQWL¿FDWLRQRIGLɣHUHQWJHQRW\SHVRIC. trachomatis (Morré 
et al. 1998; Wang et al. 1973). Genotypes A–C cause ocular infections, genotypes 
D–K cause urogenital infections and genotypes L1–L3 cause LGV. In women, 
C. trachomatis infects the columnar epithelial cells of the cervix and most (70–90%) 
of the infections remain asymptomatic (Peipert 2003). Symptoms include abnormal 
vaginal discharge and dysuria (Wiesenfeld 2017). C. trachomatis infections can also 
occur at extragenital sites, such as pharynx and rectum, and these infections are 
often asymptomatic (Chan et al. 2016). In a large study performed in the USA, the 
prevalence of C. trachomatis was 9% in rectum and 3% in pharynx among women 
(Trebach et al. 2015). Untreated or repeated C. trachomatis infections can ascend 
from the cervix to the uterus and fallopian tubes and lead to PID (Brunham et al. 
2015). PID is a risk factor for tubal damage which can lead to ectopic pregnancy 
and TFI. 
Ectopic pregnancy can be a life-threatening condition and it occurs when 
the blastocyst implants outside the uterus in either the fallopian tubes, ovaries 
or abdomen (Adachi et al. 2016). Most cases of TFI are due to salpingitis, an 
LQÀDPPDWLRQRIWKHHSLWKHOLDOVXUIDFHVRIWKHIDOORSLDQWXEHOHDGLQJWRWXEDORFFOXVLRQ
7VHYDWHWDO,WKDVEHHQVXJJHVWHGWKDWWKHLQÀDPPDWRU\UHVSRQVHVWRWKH
chlamydial heat shock protein (HSP) might be responsible for tubal damage that 
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leads to reproductive complications (Adachi et al. 2016). A C. trachomatis infection 
during pregnancy can lead to miscarriage, premature rupture of membranes, 
stillbirth, preterm delivery and low birth weight of the infant by either direct fetal 
infection, placental damage or severe maternal illness (Adachi et al. 2016). The 
mechanisms by which a C. trachomatis infection can lead to adverse pregnancy 
outcomes are only partially known. C. trachomatis might directly infect the fetus, 
WULJJHULQJDKDUPIXOLQÀDPPDWRU\UHVSRQVHRUWKHPDWHUQDOLQÀDPPDWRU\UHVSRQVH
might induce embryonic rejection due to homology of the chlamydial and human 
HSPs (Adachi et al. 2016). 
Approximating the risk for PID, ectopic pregnancy and TFI after a C. trachomatis 
infection is challenging because of the asymptomatic nature of the infection, duration 
RIWLPHEHWZHHQGLDJQRVLV ODFNRIVSHFL¿FGLDJQRVWLFFULWHULDDQGGLɣHUHQFHV LQ
study design (Davies et al. 2016; Hoenderboom et al. 2019). However, several large 
cohort studies have shown that the risk of reproductive complications is increased 
with a positive C. trachomatis test (Davies et al. 2016; den Heijer et al. 2019; 
+RHQGHUERRPHWDO5HHNLHHWDODQGWKLVULVNLVIXUWKHULQFUHDVHGZLWK
a repeated infection (Davies et al. 2016; den Heijer et al. 2019). A modelling study 
suggested that the risk for PID is 17% and the risk for salpingitis is 7% following an 
untreated C. trachomatis infection (Price et al. 2016). In addition, the same study 
estimated that 20% of PID, 5% of ectopic pregnancy and 29% of TFI are due to 
C. trachomatis. Although the incidence of ectopic pregnancy and TFI is low, 
PID caused by C. trachomatis remains the most important preventable cause of 
reproductive complications (Low et al. 2016).
C. trachomatis causes urethritis in men and approximately 30–50% of the 
infections are asymptomatic (Peipert 2003). When symptomatic, urethral discharge 
and dysuria may be reported. Extragenital infections occur also in men: the prevalence 
of C. trachomatis was 9% in rectum and 2% in pharynx among heterosexual men in a 
ODUJHVWXG\SHUIRUPHGLQWKH86$7UHEDFKHWDO6HTXHODHRIDC. trachomatis 
infection in men include epididymitis and epididymo-orchitis, and C. trachomatis 
might also be the causative agent of prostatitis (Mackern-Oberti et al. 2013). There 
LVFRQÀLFWLQJHYLGHQFHZKHWKHUFKURQLFC. trachomatis infections leading to these 
conditions may be the cause of sub-fertility or infertility in men (Gimenes et al. 
2014). Several studies have shown that a C. trachomatis infection is associated with 
SRRUVSHUPTXDOLW\LPSDLUHGVSHUPIHUWLOLVLQJFDSDFLW\DQG'1$LQWHJULW\ZKLOH
other studies demonstrated no association between C. trachomatis infection and 
DOWHUHGVSHUPTXDOLW\*LPHQHVHWDO
A urogenital C. trachomatis infection can lead to reactive arthritis in both men 
and women which often shows a remitting-relapsing disease phenotype (Gerard et 
al. 2013). It is estimated that approximately 5% of individuals with a C. trachomatis 
genital infection will develop acute reactive arthritis, and approximately a further 
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half of these develop chronic arthritis (Kvien et al. 1994). In the synovial tissue of 
patients with acute or chronic arthritis, persistent forms of C. trachomatis can be 
detected (Gerard et al. 2013). In addition, C. trachomatisW\SHVLGHQWL¿HGLQWKH
synovia were of ocular genotypes A–C and not of genital genotypes D–K, but the 
reason behind this is unknown (Gerard et al. 2010). 
The natural history of untreated C. trachomatis infections varies: infections can 
persist without symptoms for many months, can descend to the upper genital tract 
or can spontaneously resolve (Geisler et al. 2013). Human studies on the duration 
of an untreated, uncomplicated genital C. trachomatis infection have shown that 
approximately half of the infections spontaneously clear in one year after the positive 
C. trachomatis test (Geisler 2010). Some degree of protective immunity against 
C. trachomatis develops after a genital infection possibly providing protection 
against reinfection, but the duration of this immunity is unclear (Batteiger, Xu, et 
DO7KHHɣHFWRISURWHFWLYHLPPXQLW\ZDVVKRZQDPRQJVH[ZRUNHUVZKHUH
resistance to a C. trachomatis infection correlated with duration of prostitution, 
regardless of age (Brunham et al. 1996). In addition, a recent study showed that 
young women who spontaneously cleared a C. trachomatis infection were able to 
resist reinfection (Geisler et al. 2013). 
Despite the development of a partial protective immunity against C. trachomatis, 
repeated infections are extremely common. It is estimated that up to 20% of patients 
are reinfected within 12 months of treatment (Hosenfeld et al. 2009; Walker et al. 
2012). Similar rates were reported also in Finland, where 25% of women and 20% of 
PHQDFTXLUHGDUHSHDWHGLQIHFWLRQ:LNVWU|PHWDO5HSHDWHGC. trachomatis 
infections result from reinfection due to sexual contact with either an untreated 
existing partner or a new infected partner, or from failure of antibiotic therapy. In a 
study performed in the USA among adolescent women, 84% of the infections were 
reinfections and 14% were treatment failures (Batteiger, Tu, et al. 2010). 
The high rates of C. trachomatis infections observed worldwide might be due 
to early treatment interfering with the development of protective immunity, which 
HQKDQFHVVXVFHSWLELOLW\ WRUHSHDWHG LQIHFWLRQV%UXQKDP	5HNDUW7KLV
arrested immunity hypothesis is probably not the only explanation for the high 
C. trachomatis rates, as screening programmes, access to testing and changes 
in sexual behaviour can also contribute. Arrested immunity might also explain 
the declining rates of C. trachomatis VHTXHODHREVHUYHG LQPDQ\FRXQWULHV DV
early treatment prevents the infection from descending to the upper genital tract 
%UXQKDP	5HNDUW6XSSRUWLQJWKHK\SRWKHVLVWKHQXPEHURIC. trachomatis 
FDVHVQRWL¿HGE\ODERUDWRULHVLQFUHDVHGDWWKHVDPHWLPHDVVHTXHODHVXFKDV3,'
preterm delivery and ectopic pregnancy, and the C. trachomatis seroprevalence 
among fertile-aged women decreased in Finland in 1983–2003 (Lyytikäinen et al. 
5HFHQWO\LWZDVVKRZQWKDWDV\PSWRPDWLFJDVWURLQWHVWLQDOC. trachomatis 
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LQIHFWLRQVRFFXU LQKXPDQVDQGSUHVHQWDVRXUFHRISHUVLVWHQW LQIHFWLRQ 5DQN
& Yeruva 2014). The immune system and azithromycin used to treat urogenital 
infections might be unable to clear C. trachomatis from the gut, so that women 
cured of a genital infection could become reinfected by autoinoculation from the 
gastrointestinal tract, which might partly explain their high reinfection rate.
2.3.2 NEONATAL INFECTION
C. trachomatis can be vertically transmitted from mother to infant through an 
infected birth canal during child delivery resulting in neonatal conjunctivitis or 
pneumonia (Darville 2005). C. trachomatis may also infect the urogenital tract 
and rectum of the infant and these infections can be asymptomatic. Neonatal 
conjunctivitis or ophthalmia neonatorum usually develops 5–14 days after birth 
(Darville 2005). The manifestations of the disease vary from mild conjunctival 
infection to severe mucopurulent conjunctivitis, but healing without complications 
usually occurs if treated early. Neonatal C. trachomatis pneumonia is usually mild 
and afebrile and occurs between one and three months of age (Darville 2005). 
Symptoms of neonatal pneumonia include nasal obstruction and/or discharge, 
tachypnea and a repetitive staccato cough. Untreated pneumonia can persist 
for several weeks and can lead to poor feeding and diminished weight gain. 
C. trachomatis neonatal pneumonia may also lead to asthma and chronic lung 
disease later in life (Adachi et al. 2016). 
Prenatal screening and treatment of C. trachomatis infections in pregnant 
women have lowered the incidence of neonatal infections, but only few countries 
have implemented such programmes (Adachi et al. 2016). In Finland, opportunistic 
screening is available to both symptomatic and asymptomatic pregnant women. 
The estimated risk of transmission of C. trachomatis to the infant during childbirth 
is approximately 50%, and pneumonia develops in 10–20% of infants exposed to 
C. trachomatis (Hammerschlag 2011). In Finland, C. trachomatis infections among 
infants are rare (0.22 per 1000 live births) and the risk of vertical transmission from 
C. trachomatisSRVLWLYHPRWKHUVWRQHRQDWHVLVVLJQL¿FDQWO\ORZHUWKDQSUHYLRXVO\
reported, less than 2% (Honkila et al. 2017). 
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2.3.3 LYMPHOGRANULOMA VENEREUM (LGV) 
In contrast to the mucosal urogenital infections caused by C. trachomatis genotypes 
D–K, C. trachomatis invasive genotypes L1–L3 cause an LGV infection in the 
lymphatic system. Sexually transmitted LGV infections are endemic in parts of 
Africa, Asia, South America, and in some Caribbean islands (Mabey & Peeling 2002). 
7KHFODVVLFFOLQLFDOPDQLIHVWDWLRQRIDQ/*9LQIHFWLRQSURJUHVVHVLQGLɣHUHQWVWDJHV
(de Vries 2019). In the primary stage, a painless papule or a shallow ulcer appears 
in the epithelia at the infection site and it usually heals in a few days. After 2–6 
weeks, in the secondary stage, the infection spreads to the inguinal or femoral lymph 
QRGHVZLWKWKHIRUPDWLRQRIVHYHUHO\PSKDGHQRSDWK\VWULFWXUHVDQG¿VWXODV,IOHIW
XQWUHDWHGODWHPDQLIHVWDWLRQVRI/*9LQWKHWHUWLDU\VWDJHLQYROYHVHYHUHGLV¿JXULQJ
conditions of the external genitalia, such as elephantiasis and esthiomene. 
After the introduction of antibiotics, classic LGV infections were rarely 
encountered in the Western countries and were considered mainly as imports 
from endemic countries (Mabey & Peeling 2002). In 2003, several outbreaks due 
to the C. trachomatis genotypes L were reported in Europe, North America and 
Australia (Martin-Iguacel et al. 2010; Nieuwenhuis et al. 2004). LGV infections were 
observed mainly among MSM who were often HIV positive, had other concomitant 
sexually transmitted infections such as syphilis, gonorrhoea or hepatitis C, and 
presented high risk sexual behaviour involving international networks. In contrast 
to the classic lymphadenopathy, LGV infections manifested mainly as proctitis with 
symptoms such as anal cramps, tenesmus, constipation, discharge and pain. In 
addition, asymptomatic proctitis was reported. 
,Q)LQODQG/*9LQIHFWLRQVKDYHEHHQQRWL¿HGE\FOLQLFLDQVWRWKH1,'5VLQFH
1932. At the beginning of the 1930s, there were almost 200 reported cases of LGV 
in Finland, and the prevalence of LGV decreased towards the end of the 1930s with 
29 LGV cases in 1939 (Olin 1941). Since then LGV infections remained practically 
non-existent in Finland until 2009. 
2.3.4 TRACHOMA 
Trachoma, an eye infection caused by C. trachomatis genotypes A–C, is the most 
common infectious cause of blindness worldwide (Taylor et al. 2014). Trachoma 
DɣHFWVPLOOLRQSHRSOHZLWKDSSUR[LPDWHO\PLOOLRQEOLQGHGRUVHYHUHO\YLVXDOO\
LPSDLUHGDQGPLOOLRQSHRSOHVXɣHULQJIURPFRUQHDOGDPDJH0DULRWWLHWDO
2009). These eye infections are rarely seen in Europe and North America and occur 
mostly in the developing countries of Africa and Asia. Infections are transmitted 
through infected ocular secretions among children whose facial cleanliness is poor. 
5HSHDWHGLQIHFWLRQVZLWKC. trachomatis in childhood result in severe conjunctival 
LQÀDPPDWLRQFRQMXQFWLYDOVFDUULQJGLVWRUWLRQRIWKHH\HOLGDQGLQWXUQHGH\HODVKHV
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touching the cornea which can lead to blindness in later life. Control programmes 
against trachoma have been implemented, and trachoma has been successfully 
eliminated in several countries (Taylor et al. 2014). The goal of these programmes 
is to eliminate trachoma worldwide by 2020. Control measures include surgery of 
the eyelids, mass distribution of antibiotics, promotion of facial cleanliness, and 
environmental improvement with access to clean water and sanitation.
2.4 DEVELOPMENTAL CYCLE OF C. TRACHOMATIS
As an obligate intracellular bacterium, C. trachomatis replicates only in a host 
cell with a special two-phase growth cycle, which involves complex interactions 
EHWZHHQWKHEDFWHULDDQGWKHKRVW$EGHO5DKPDQ	%HOODQG)LJXUH7KH
intracellular lifestyle of C. trachomatisHQDEOHVWKHDFTXLUHPHQWRIHVVHQWLDOKRVW
FHOOQXWULHQWVDQGRɣHUVSURWHFWLRQIURPWKHGHIHQFHPHFKDQLVPVRIWKHKRVWFHOO
The developmental cycle begins when the infectious form, the elementary body 
(EB), attaches to the host cell membrane through interactions between bacterial 
adhesins, host receptors and host heparan sulphate proteoglycans (Elwell et al. 
(%VLQMHFWWKHSUHV\QWKHVLVHGHɣHFWRUSURWHLQVVXFKDVWKHWUDQVORFDWHGDFWLQ
recruiting phosphoprotein (Tarp) through the type III secretion system (T3SS) to 
WKHKRVWF\WRVRO&OLIWRQHWDO7KHVHHɣHFWRUVPRGXODWHKRVWFHOOVLJQDOOLQJ
and actin cytoskeleton rearrangement and facilitate the entry of the EB into the 
host cell via endocytosis. The EB has previously been considered to be metabolically 
inactive, but recent studies show that also EBs present metabolic activity and utilise 
GLɣHUHQWHQHUJ\VRXUFHVWRPDLQWDLQLQIHFWLYLW\*ULHVKDEHUHWDO2PVODQG
et al. 2012).
After endocytosis, the EBs are enclosed in a membrane-bound vacuole called 
inclusion and start to transform to larger and highly metabolically active reticulate 
ERGLHV5%V(OZHOOHWDO(DUO\5%HɣHFWRUVSURGXFHGDW±KRXUVSRVW
infection (hpi) facilitate the remodelling of the inclusion membrane, redirect exocytic 
YHVLFOHWRWKHLQFOXVLRQWRSURPRWHQXWULHQWDFTXLVLWLRQDQGSUHYHQWIXVLRQZLWK
O\VRVRPHVE\LQKLELWLQJLQWHUDFWLRQZLWKWKHHQGRF\WLFSDWKZD\5%VDUHWUDQVSRUWHG
along microtubules to the microtubule organising centers or centrosomes near the 
SHUL*ROJLUHJLRQ$WKSL5%VDFWLYHO\UHSOLFDWHDQGGLYLGHE\ELQDU\¿VVLRQDQG
they are closely associated to the inner face of the inclusion membrane. During this 
SKDVHWKHVL]HRIWKH LQFOXVLRQJURZVDQG5%VPXVWDFTXLUHHVVHQWLDO OLSLGVIRU
growth and survival (Gitsels et al. 2019). To achieve this, the inclusion interacts with 
intercepting vesicles from organelles in the peri-Golgi region through vesicular and 
QRQYHVLFXODUWUDQVSRUWSDWKZD\V,QDGGLWLRQWRWKHDFTXLVLWLRQRIQXWULHQWVDQG
OLSLGV5%HɣHFWRUVDFWLYDWHSUROLIHUDWLRQDQGVXUYLYDOSDWKZD\VLQKLELWDSRSWRWLF
pathways and modulate the innate immune signalling of the host (Elwell et al. 2016). 
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$IWHUVHYHUDOKRXUVRIUHSOLFDWLRQDQGFHOOGLYLVLRQ5%VDV\QFKURQRXVO\WUDQVIRUP
back to EBs at 18–24 hpi. Late C. trachomatisHɣHFWRUVLQFOXGHRXWHUPHPEUDQH
complex proteins and DNA binding histone proteins, which condense DNA and 
VZLWFKRɣWKHWUDQVFULSWLRQRIPDQ\JHQHV(OZHOOHWDO/DWHHɣHFWRUSURWHLQV
are packaged into forming EBs to be released in the next cycle of infection, and EBs 
exit the host cell via cell lysis or extrusion at 48 hpi. 
8QGHU FHUWDLQ HQYLURQPHQWDO SUHVVXUH5%V FDQ WUDQVIRUP WRQRQGLYLGLQJ
persistent forms in which they are viable but non-cultivable (Panzetta et al. 2018). 
This persistence can be induced by beta-lactam antibiotics, interferon-gamma 
(IFN-J), and by the deprivation of iron or amino acids. Persistent or aberrant 
forms continue to replicate DNA and synthesise proteins, but cell division is halted. 
3HUVLVWHQWIRUPVFDQWUDQVIRUPEDFNWR5%VZKHQWKHHQYLURQPHQWDOVWUHVVIDFWRUV
DUHUHPRYHG$OWKRXJKSHUVLVWHQFHPLJKWOHDGWRFKURQLFLQÀDPPDWLRQDQGVFDUULQJ
it is not known whether persistence occurs in vivo. The evidence for persistence 
in humans is so far indirect, as it is based on the direct observation of persistent 
forms in infected tissue, such as endocervical cells (Lewis et al. 2014). Persistent 
forms have been shown to be resistant to azithromycin, which is of importance 
DVD]LWKURP\FLQLVWKH¿UVWOLQHDQWLELRWLFXVHGWRWUHDWC. trachomatis urogenital 
infections (Wyrick & Knight 2004).
EB 
endocytosis 
EB transforms to RB (2-8 hpi) 
Persistence 
Replication 
of RBs  
(12 hpi) 
Exit of EBs 
(48 hpi) 
RBs 
transform 
to EBs 
(18-24 hpi) 
Figure 2. The developmental cycle of C. trachomatis. The infectious elementary body (EB) enters the host 
cell by endocytosis and transforms to a metabolically active reticulate body (RB) at 2–8 hours post infection 
(hpi). Inside the inclusion, RBs replicate and divide by binary fission (12 hpi) or they can transform to non-
dividing persistent forms in the presence of growth inhibitors. Persistent forms can transform back to RBs 
when the inhibitor is removed. After several hours of replication, RBs begin to transform back to EBs (18–24 
hpi) and EBs exit the host cell to infect new cells (48 hpi). Modified from Brunham & Rey-Ladino (2005). 
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2.5 HOST IMMUNE RESPONSE AGAINST C. TRACHOMATIS
5HSOLFDWLRQLQVLGHWKHLQFOXVLRQRɣHUVSURWHFWLRQWRC. trachomatis, as exposure to 
antibodies and antigen-processing and -presentation mechanism of the host is limited. 
The immune response of the host against C. trachomatis is dynamic and involves 
cells and mediators from both innate and adaptive immunity (Vasilevsky et al. 2014). 
C. trachomatis is recognised by the host cell by receptors of the innate immune 
V\VWHPFDOOHGSDWWHUQUHFRJQLWLRQUHFHSWRUV355VXFKDVWKHWROOOLNHUHFHSWRUV
&KHQHWDO355VUHFRJQLVHFHUWDLQVWUXFWXUHVRIEDFWHULDFDOOHGSDWKRJHQ
associated molecular patterns, for example peptidoglycan or lipopolysaccharide 
/367KLVWULJJHUVWKHUHOHDVHRISURLQÀDPPDWRU\F\WRNLQHVDQGFKHPRNLQHV
ZKLFK DWWUDFWV LQÀDPPDWRU\ FHOOV 7KH F\WRNLQHV SURGXFHG E\ HSLWKHOLDO FHOOV
polarise the immune response towards a protective Type 1 helper T cell response, 
and immunity to C. trachomatis is largely mediated by CD4+ T cells producing 
IFN-J. The secreted chemokines and T cell responses mediating the elimination of 
bacteria are also responsible for C. trachomatis related immunopathology, such as 
tissue damage and scarring, and may result from a shift from Type 1 helper T cell 
to Type 2 helper T cell immunity (Vasilevsky et al. 2014). 
C. trachomatis can manipulate the immune response of the host by several 
mechanisms, which can rescue the bacteria from clearance, but also contribute to the 
asymptomatic nature of chlamydial infections. IFN-J secreted by T cells decreases 
the intracellular tryptophan levels via indoleamine 2,3-dioxygenase. Chlamydia 
are auxotrophic for tryptophan and respond to this stress with the formation of 
SHUVLVWHQWQRQGLYLGLQJIRUPVZKLFKPD\WUDQVIRUPEDFNWR5%VZKHQWU\SWRSKDQ
is again available. Urogenital C. trachomatis strains can respond to this deprivation 
by synthesising tryptophan from indole, which is produced by other bacteria in 
WKHYDJLQDOÀRUD)HKOQHU*DUGLQHUHWDO1XFOHDUIDFWRUǉB (NF-ǉB) is an 
important protein complex of the host that regulates DNA replication, cytokine 
production and cell survival. C. trachomatisKDVHYROYHGGLɣHUHQWVWUDWHJLHVWREORFN
the transcription of NF-ǉB to enhance intracellular survival (Chen et al. 2019). 
C. trachomatis can block the degradation of the NF-ǉB retention factor and prevent 
the nuclear translocation of NF-ǉB which inhibits NF-ǉB transcription.
2.6 C. TRACHOMATIS GENOME 
7KHVHTXHQFHRIWKH¿UVWC. trachomatis genome (genotype D) was published in 
1998 (Stephens et al. 1998), and was followed by genomes from C. trachomatis 
genotype A (Carlson et al. 2005), and two genomes from C. trachomatis genotype L2 
(Thomson et al. 2008). These genomes showed a strikingly high degree of similarity 
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LQ WHUPV RI VL]H QXFOHRWLGH VHTXHQFH VLPLODULW\ ! LGHQWLFDO DQG V\QWHQ\
7DEOH7ZHQW\\HDUVODWHUZKROHJHQRPHVHTXHQFLQJ:*6WHFKQRORJLHVKDYH
advanced in terms of reduced time and cost, and now there are approximately 180 
C. trachomatis genomes in the National Center for Biotechnology Information 
(NCBI) genome database (https://www.ncbi.nlm.nih.gov/genome/), and 
approximately 200 genomes in the European Nucleotide Archive (ENA) 
(https://www.ebi.ac.uk/ena/) of the European Bioinformatics Institute. 
Table 2. Properties of the C. trachomatis genomes of genotypes D, A and L2.  
Modified from Thomson et al. (2008). 
Strain UW-3/CXa Har-13b 434/Buc
Genotype D A L2
Biovar genital ocular LGV
Chromosome size (bp) 1 042 519 1 044 459 1 038 842
Plasmid size (bp) 7 493 7 510 7 499
G+C content (%) 41.27 41.27 41.33
Predicted proteins 894 920 889
LGV, lymphogranuloma venereum; bp, base pairs; 
a (Stephens et al. 1998); b (Carlson et al. 2005); c (Thomson et al. 2008)
WGS of C. trachomatis revealed a relatively small genome of 1.04 mega base 
pair (Mb) (Carlson et al. 2005; Stephens et al. 1998; Thomson et al. 2008). The 
C. trachomatis genome encodes a set of genes close to the minimum needed for DNA 
replication, transcription and translation. However, DNA repair and recombination 
mechanisms are vastly represented in the genome. The C. trachomatis genome 
includes the genes needed for the essential functions in aerobic respiration, but lacks 
many genes encoding metabolic enzymes, which makes this bacterium reliant on the 
KRVWIRUPDQ\RILWVPHWDEROLFUHTXLUHPHQWVC. trachomatis was initially considered 
to be a strict energy parasite, but genome analysis revealed the necessary genes for 
DGHQRVLQHWULSKRVSKDWH$73JHQHUDWLRQDQG$73WUDQVORFDVHVHPSOR\HGWRDFTXLUH
ATP from the host. Some C. trachomatisJHQHVZHUHDFTXLUHGIURPHXNDU\RWHV
such as the genes encoding chromatin-associated domain proteins, which may act 
in chlamydial nucleoid condensation and de-condensation. The C. trachomatis 
genome includes the genes for peptidoglycan biosynthesis, and Chlamydia are 
susceptible to antibiotics that target peptidoglycan, but it was just until recently that 
the C. trachomatisFHOOZDOOZDV¿QDOO\SURYHQWRFRQWDLQSHSWLGRJO\FDQ/LHFKWLHW
al. 2014). The importance of pathogenicity is well represented in the C. trachomatis 
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JHQRPHDVDSSUR[LPDWHO\RIWKHJHQRPHHQFRGHVYLUXOHQFHHɣHFWRUV(OZHOO
et al. 2016).
In addition to the similarities between the genomes of genotypes A, D and L2, 
GLɣHUHQFHVH[LVWHVSHFLDOO\LQWKHNLOREDVHSDLUNESODVWLFLW\]RQHLQWKHompA 
gene encoding the MOMP, among the polymorphic membrane protein gene family 
members (pmp) encoding polymorphic membrane proteins (Pmp), and among inc 
genes encoding inclusion membrane proteins. The chlamydial cytotoxin gene (tox) 
residing in the plasticity zone is intact in the genital C. trachomatis strains, but in 
ocular and LGV strains there are extensive deletions in the tox gene (Belland et al. 
2001; Carlson et al. 2004). Genital genotypes of C. trachomatis have a trpBA operon 
encoding tryptophan synthase, but ocular genotypes have accumulated mutations in 
the genes of the operon that inactivate the enzyme (Fehlner-Gardiner et al. 2002). 
6HTXHQFHYDULDWLRQZLWKLQpmp genes distinguishes between the ocular, genital 
and LGV types of C. trachomatis (Stothard et al. 2003). These dissimilarities in 
WKHJHQRPHVPLJKWH[SODLQWKHGLɣHUHQFHVLQWLVVXHWURSLVPDQGGLVHDVHRXWFRPH
among the ocular, genital and LGV types of C. trachomatis.
The C. trachomatis genome was considered to be highly conserved due to the 
obligate intracellular niche of Chlamydia. However, WGS analyses have revealed 
that gene duplications, point mutations, insertions, deletions and horizontal gene 
transfer occur in the chlamydial genome (Abdelsamed et al. 2013). In addition, it is 
now known that in ChlamydiaUHFRPELQDWLRQIUHTXHQWO\WDNHVSODFHERWKin vitro 
-HɣUH\HWDODQGin vivo+DG¿HOGHWDO
Many Chlamydia species including C. trachomatis contain a highly conserved 
7.5 kb long cryptic plasmid with copy numbers of 4–10 per host cell (Zhong 2017). 
Plasmid-free strains have been described which suggests that the cryptic plasmid 
is not essential for growth or infectivity of the bacteria. However, the plasmid is an 
important virulence factor of C. trachomatis. Plasmid-free C. trachomatis causes 
attenuated infections with decreased loads of organisms or shorter duration that 
spontaneously resolve with reduced or no post-infection pathology. The plasmid 
HQFRGHVHLJKWRSHQUHDGLQJIUDPHV25)VFDOOHGSODVPLGJO\FRSURWHLQV3JS±
3XWDWLYH IXQFWLRQVRIVHYHUDO25)VKDYHEHHQDVVLJQHGEDVHGRQ WKHKRPRORJ\
to known proteins in the public databases. Pgp1 is homologous to a helicase 
involved in the unwinding of double-stranded DNA during replication. Pgp7 and 
Pgp8 are involved in the plasmid replication, and Pgp5 is a homologue of plasmid-
partitioning proteins. Pgp2 and Pgp6 are ChlamydiaVSHFL¿FSURWHLQVVKRZLQJ
little or no homology to proteins in the public databases. Pgp3 is highly conserved 
among Chlamydia and is secreted into the host cytosol of infected cells, and it may 
neutralise host antimicrobial peptides. Pgp4 regulates the expression of Pgp3 and is 
largely responsible for the plasmid-mediated regulation of chlamydial chromosomal 
gene expression (Song et al. 2013). The most highly regulated genes include those 
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HQFRGLQJIRUJO\FRJHQV\QWKDVH3PSOLNHSURWHLQVDQGSXWDWLYH766HɣHFWRUV7KH
plasmid is also a negative regulator of the expression of the chlamydial protease-
like activity factor (CPAF) for the L2 genotype (Patton et al. 2018). 
Two factors have limited research on the biology of Chlamydia infections. The 
¿UVWLVWKHODFNRIDKRVWIUHHV\VWHPIRUJURZLQJChlamydia and the second is the 
absence of methods for transformation and genetic manipulation of Chlamydia. 
Unfortunately, a host-free method for C. trachomatis culture is still lacking, but 
UHFHQWO\WKHUHKDYHEHHQPDMRUDGYDQFHVLQWKHWHFKQLTXHVDGGUHVVLQJWKHODWWHU
issue. A shuttle vector based on the chlamydial plasmid was stably introduced 
into C. trachomatis:DQJHWDO7KLVWUDQVIRUPDWLRQWHFKQLTXHZDVZLGHO\
adopted by other groups with minor variations. Also genetic manipulation of 
Chlamydia is now possible using a method that allows targeting chlamydial 
genes for deletion or allelic exchange, as well as curing plasmids with a novel 
VXLFLGHYHFWRU0XHOOHUHWDO5HFHQWO\DFOXVWHUHGUHJXODUO\LQWHUVSDFHG
short palindromic repeats interference was used to repress the gene expression 
of C. trachomatis (Ouellette 2018).
2.7 C. TRACHOMATIS GENE EXPRESSION
C. trachomatis gene expression exhibits temporal patterns, which regulate the 
GLɣHUHQWVWDJHVRIWKHFKODP\GLDOGHYHORSPHQWDOF\FOH(DUO\JHQHVDUHH[SUHVVHG
within one to three hours after endocytosis, mid-cycle genes start expression during 
5%UHSOLFDWLRQDQGFHOOGLYLVLRQDQGODWHJHQHVDUHWUDQVFULEHGZKHQ5%VFRQYHUW
to EBs (Belland et al. 2003; Nicholson et al. 2003; Shaw et al. 2000). 
The temporal gene expression of C. trachomatis in vitro has been studied with 
Northern blot analysis (Stephens, Wagar, & Edman 1988) and real-time polymerase 
FKDLQUHDFWLRQ3&5(Mathews et al. 1999)RUUHYHUVHWUDQVFULSWDVH3&5573&5
using agarose gel electrophoresis (Shaw et al. 2000). Whole transcriptome analyses 
have been performed with single isolates of C. pneumoniae (Albrecht et al. 2011; 
Maurer et al. 2007) and C. trachomatis (Albrecht et al. 2010; Ferreira et al. 2017; 
Humphrys et al. 2013)DWDVSHFL¿FSKDVHRIWKHGHYHORSPHQWDOF\FOH
The C. trachomatis gene expression studies have mainly been performed with 
laboratory reference strains propagated in the laboratory for decades (Belland et 
DO1LFKROVRQHWDO3UHYLRXVVWXGLHVKDYHGHPRQVWUDWHGWKHHɣHFWVRI
long-term propagation on the C. trachomatis genome, gene expression and growth 
dynamics. In one study, repeated laboratory passages resulted in interrupting 
mutations in the gene CT135 among low-passage-number genital clinical strains 
(Bonner et al. 2015). In another study, the gene expression of many virulence 
factors including the Tarp was downregulated, and an increase in growth rates 
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was observed among clinical strains (ocular, genital and LGV) after long-term 
propagation (Borges et al. 2015). In addition, heterogeneity in the population of the 
JHQLWDOVWUDLQVDɣHFWLQJWKHVHTXHQFHRIWKHtox gene led to a potentially disrupted 
F\WRWR[LQ2QO\DVLQJOHVWXG\REVHUYHGIHZDGDSWLYHPXWDWLRQVDQGQRVLJQL¿FDQW
GLɣHUHQFHVLQWKHJURZWKUDWHVLQDJHQLWDOFOLQLFDOVWUDLQDIWHURQH\HDURIVHULDO
passaging (Borges et al. 2013).
The studies analysing the gene expression of both C. trachomatis reference and 
low-passage-number clinical strains during the chlamydial developmental cycle are 
few. One study analysed the expression of the C. trachomatis ompA gene throughout 
the developmental cycle using both reference and clinical strains, and in this study 
the gene expression levels of the reference and clinical strains did not correlate 
(Nunes et al. 2007). To our knowledge, no studies have been conducted analysing 
the expression of chlamydial virulence genes, such as tarp and tox, or cpaf which 
encodes a chlamydial protease, using clinical low-passage-number strains during 
WKHGLɣHUHQWVWDJHVRIWKHGHYHORSPHQWDOF\FOH
Gene expression of C. trachomatis in cell culture is fairly well known, but gene 
expression during in vivo infection remains somewhat unexplored. In addition, it 
is not known to what extent gene expression in vitro correlates to the situation in 
human infection. Only a few studies are describing the in vivo expression of selected 
C. trachomatis genes. The expression of chlamydial HSP genes was studied directly 
from cervical cells (Jha et al. 2009) and synovial biopsies (Gerard et al. 2013).
2.8 C. TRACHOMATIS PROTEOME AND EFFECTOR PROTEINS
The genome of C. trachomatis encodes approximately 900 predicted proteins 
(Carlson et al. 2005; Stephens et al. 1998; Thomson et al. 2008). About two-thirds 
RIWKHSURWHLQVDUHVKDUHGDFURVVVSHFLHVZKLFKUHÀHFWVWKHJHQHWLFFRQVHUYDWLRQ
of Chlamydia (OZHOO HW DO  (ɣHFWRU SURWHLQV DUH WUDQVORFDWHG WR WKH
bacterial surface by the type V secretion system, to the inclusion lumen by the 
type II secretion system, and into the host cell or inclusion membrane by the T3SS. 
C. trachomatisKDVEHHQVKRZQWRGHOLYHUDWOHDVWGLɣHUHQWHɣHFWRUSURWHLQVWRWKH
LQFOXVLRQPHPEUDQHDQGWKHKRVWF\WRSODVP%XJDOKmR	0RWD$TXDQWLWDWLYH
SURWHRPLFV VWXG\RQ WKH WZRGLɣHUHQWGHYHORSPHQWDO IRUPVRIC. trachomatis 
revealed that EBs are primed for high T3SS capacity and for generating a burst of 
HQHUJ\YLDJOXFRVHFDWDEROLVPWRIXHOWKH(%WR5%WUDQVIRUPDWLRQ6DNDHWDO
5%VDUHSULPHGIRUUREXVWSURWHLQV\QWKHVLVQXWULHQWWUDQVSRUWWKHDFFXPXODWLRQ
RI$73HɤFLHQWUHSOLFDWLRQDQGXOWLPDWHO\IRUWKHWUDQVIRUPDWLRQRI5%VWR(%V
Another proteomics study showed that EBs are metabolically active and have the 
capacity to generate ATP, and most of the enzymes involved in peptidoglycan 
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ELRV\QWKHVLVZHUHGHWHFWHGLQ5%V6NLSSHWDO7KHGDWDDFKLHYHGZLWKWKH
proteomic analyses correlate well with the results from genomic (Carlson et al. 2005; 
Stephens et al. 1998; Thomson et al. 2008) and transcriptional studies (Albrecht 
et al. 2010; Belland et al. 2003).
Among the most extensively studied C. trachomatisHɣHFWRUSURWHLQVDUH&3$)
FRGLQJVHTXHQFHQXPEHU&77DUS&7DQGFKODP\GLDOF\WRWR[LQ&7
CPAF is a potent type II secreted protease which is detected in the host cell cytosol 
6QDYHO\HWDO=KRQJHWDO0DQ\RIWKHSUHYLRXVO\UHSRUWHGHɣHFWVRI
&3$)KDYHEHHQTXHVWLRQHG&KHQHWDOEXWLWVHHPVWKDW&3$)KDVDUROH
in the later stages of infection during the exit of EBs (Snavely et al. 2014). Tarp is 
translocated into the host cell by T3SS where it is tyrosine phosphorylated by host 
kinases (Clifton et al. 2004). It is a multidomain protein that directly associates 
ZLWKDFWLQDQGLVLQYROYHGLQVHYHUDOGLɣHUHQWVLJQDOOLQJHYHQWVWKDWOHDGWRDFWLQ
recruitment and internalisation of the EB promoting intracellular survival of 
Chlamydia (Elwell et al. 2016). The chlamydial cytotoxin residing in the plasticity 
zone inactivates intracellular regulatory molecules such as the GTP-binding proteins 
RIWKH5KR5DVIDPLO\E\JO\FRV\ODWLRQZKLFKLQGXFHVDFWLQGHSRO\PHULVDWLRQRIWKH
host cell promoting the entry of the EB (Belland et al. 2001; Thalmann et al. 2010). 
Cytotoxin has also been shown to be involved in delayed cell cycle progression and 
multinucleation of the host cell (Bothe et al. 2015).
MOMP is the principal outer membrane protein and surface antigen of 
C. trachomatis. The size of MOMP is 40 kDa and it constitutes 60% of the proteins 
on the outer membrane (Caldwell et al. 1981). MOMP maintains the structure of 
(%DQGLQVLGHWKHKRVWFHOO0203WUDQVIRUPVLQWRDSRULQWKURXJKZKLFK5%VFDQ
DFTXLUHQXWULHQWV7KLVWUDQVIRUPDWLRQRFFXUVE\VXOSKXUEULGJHVZLWKLQ0203
DQGEHWZHHQ0203DQGRWKHURXWHUPHPEUDQHSURWHLQV0203FRQVLVWVRI¿YH
constant domains (CD) CD1–5 and four variable domains (VD) VD1–4 (Stephens 
et al. 1987) (Figure 3). The hydrophobic membrane-spanning CDs anchor MOMP 
to the outer membrane. The hydrophilic, surface-exposed epitopes of VD1, VD2 and 
VD4 stimulate the production of neutralising antibodies. In addition, the epitopes 
RI9'DQG9'VWLPXODWHWKHSURGXFWLRQRIVHURW\SHVSHFL¿FDQWLERGLHVDQGWKH
epitopes of VD4 stimulate the production of serogroup and C. trachomatisVSHFL¿F
antibodies (Baehr et al. 1988; Stephens, Wagar, & Schoolnik 1988).
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Figure 3. The structure of the major outer membrane protein (MOMP) of C. trachomatis. MOMP is 
anchored to the lipopolysaccharide (LPS)-containing outer membrane (OM) by five hydrophobic 
constant domains (CD) CD1–5. The four surface-exposed, hydrophilic variable domains (VD) VD1–4 
stimulate the production of antibodies. Modified from Kim & DeMars (2001). 
Another group of proteins located on the outer membrane of C. trachomatis are 
the Pmps. Genes pmpA–IHQFRGHQLQHGLɣHUHQW3PSVZKLFKDUHDXWRWUDQVSRUWHUV
and adhesins, important in the initial phase of a C. trachomatis infection (Vasilevsky 
et al. 2016). Pmps as typical autotransporters include a cleavable N-terminal Sec-
GHSHQGHQWOHDGHUVHTXHQFHIRUORFDOLVDWLRQWRWKHPHPEUDQHDSDVVHQJHUGRPDLQ
for surface localisation or secretion, and a C-terminal ǃEDUUHOWUDQVORFDWRUVHTXHQFH
for outer membrane translocation. Pmps are large (90–187 kDa) (Stothard et al. 
2003), and like MOMP, Pmps as surface-exposed proteins elicit a host immune 
response, of which PmpB, PmpC, PmpD and PmpI are the most immunogenic 
(Vasilevsky et al. 2016). Pmps, as well as MOMP, are potential candidates utilised 
as components of a subunit C. trachomatis vaccine (de la Maza et al. 2017). 
2.9 TYPING OF C. TRACHOMATIS
Typing of C. trachomatis is used for epidemiological, diagnostic and research 
purposes. It can reveal transmission networks, distinguish reinfection from treatment 
failure, and separate LGV from non-LGV infections (de Vries et al. 2015). First 
C. trachomatis typing methods were based on the characterization of the MOMP 
XVLQJVSHFL¿FDQWLERGLHV6HURW\SLQJZDV¿UVWSHUIRUPHGZLWKSRO\FORQDODQGODWHU
ZLWKPRQRFORQDODQWLERGLHVXVLQJWKHPLFURLPPXQRÀXRUHVFHQFH0,)WHVW:DQJ
HWDO7KLVPHWKRGUHTXLUHVKLJKTXDQWLWLHVRIOLYLQJEDFWHULDQRQVWDQGDUGLVHG
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antibodies, and it is expensive and laborious. The sero-immunological analysis of 
the C. trachomatis0203OHGWRWKHLGHQWL¿FDWLRQRIGLɣHUHQWVHURW\SHV:DQJ
HWDO7KHVHVHURW\SHVDUHGLYLGHGLQWRWKUHHGLɣHUHQWJURXSVWKH%JURXS
includes serotypes B, Ba, E, D, L1 and L2, the C group includes serotypes C, A, H, 
,-.DQG/DQGWKHLQWHUPHGLDWHJURXSLQFOXGHVVHURW\SHV)DQG*6HTXHQFH
GLɣHUHQFHVLQWKHompA gene encoding MOMP, especially in the regions encoding 
WKHYDULDEOHGRPDLQVRI0203ODWHUFRQ¿UPHGWKLVGLVFULPLQDWLRQ0RUUpHWDO
1998). The serological properties and the ompAJHQHVHTXHQFHVZLWKLQDJURXSDUH
almost identical (Morré et al. 1998; Yuan et al. 1989). 
Molecular typing methods followed serotyping, and the culture of C. trachomatis 
ZDVQRORQJHUQHFHVVDU\7KH¿UVWJHQRW\SLQJPHWKRGVZHUHPDLQO\EDVHGRQWKH
analysis of the ompAJHQHVHTXHQFHVHQFRGLQJWKH9'±RI0203:LWKWKH
UHVWULFWLRQ IUDJPHQW OHQJWKSRO\PRUSKLVP5)/3PHWKRG WKHC. trachomatis 
ompA JHQH LV DPSOL¿HGZLWK 3&5 3&5 SURGXFWV DUH GLJHVWHG ZLWK GLɣHUHQW
restriction enzymes, restriction products are analysed on agarose gel electrophoresis 
and the results are compared to type strains (Frost et al. 1991). The limiting factor 
ZLWKWKH5)/3PHWKRGLVWKHQXPEHURIGLɣHUHQWUHVWULFWLRQHQ]\PHVDYDLODEOH7KH
ompAJHQHFDQDOVREHDPSOL¿HGE\3&5DQGVHTXHQFHG%DQGHDHWDORU
WKHGLɣHUHQWJHQRW\SHVFDQEHGHWHFWHGZLWKVSHFL¿FÀXRUHVFHQWSUREHVE\UHDOWLPH
3&5-DODOHWDO&RQWUDU\WRWUDGLWLRQDOVHURW\SLQJZKLFKGRHVQRWUHYHDO
mutations, ompA genotyping may do so. 
More detailed typing compared to the serotyping or ompA genotyping methods 
ZDVDFKLHYHGZLWKKLJKUHVROXWLRQW\SLQJWHFKQLTXHVVXFKDVPXOWLORFXVVHTXHQFH
typing (MLST) and multi locus variable number tandem repeat analysis (MLVA). 
0/67LVXVHGWRDQDO\VHVHTXHQFHVRIVHYHUDOSRO\PRUSKLFORFLHDFKORFXVLVDVVLJQHG
DQDOOHOHQXPEHUDQGDOOHOHQXPEHUVFRQVWLWXWHWKHSUR¿OHRIWKHVWUDLQ LH WKH
VHTXHQFHW\SH0/67PHWKRGVGHYHORSHGIRUC. trachomatis have analysed highly 
variable regions (Klint et al. 2007) and house-keeping genes (Pannekoek et al. 2008). 
In MLVA, several genomic variable number of tandem repeats loci are analysed. The 
QXPEHURIUHSHDWVLQGLɣHUHQWORFLLVGHWHUPLQHGDQGWKHQXPEHUVHULHVGHVFULEHV
WKHSUR¿OHRIWKHVWUDLQDQGGHVLJQDWHVWKHVHTXHQFHW\SH3HGHUVHQHWDO
7KHJHQHWLFORFLXVHGLQWKHVH0/67DQG0/9$WHFKQLTXHVKDYHSURYHQWREHYHU\
stable after multiple rounds of cell culture, which makes these methods suitable for 
use in the epidemiologic analyses of C. trachomatis (Labiran et al. 2012). 
WGS can produce a wealth of data, which can be used in discriminating even 
the most closely related C. trachomatis strains. In the future, the focus of genome 
DQDO\VLV ZLOO PRVW SUREDEO\ EH VZLWFKHG IURP VHTXHQFLQJ VLQJOH JHQRPHV WR
SHUIRUPLQJODUJHVFDOHZKROHSRSXODWLRQDQDO\VHVIRFXVLQJRQ¿QHVFDOHVHTXHQFH
analysis searching for single nucleotide polymorphisms (SNP) in different 
C. trachomatisVWUDLQV+DG¿HOGHWDO3UHYLRXVO\VDPSOHVKDGWREHFXOWXUHG
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WR SURGXFH ODUJH TXDQWLWLHV RI EDFWHULDO JHQRPHV IRU:*6 EXW QRZ FXOWXUH
independent methods are also available (Seth-Smith et al. 2013).
2.10 DIAGNOSIS OF C. TRACHOMATIS INFECTIONS
2.10.1 CULTURE
 
C. trachomatis can be isolated using cell lines such as McCoy, HeLa229 and 
%XɣDOR*UHHQ0RQNH\.LGQH\FHOOV3DSSHWDO6SHFLPHQVDUHFHQWULIXJHG
RQWR FRQÀXHQW FHOOPRQROD\HUV DQG LQFXEDWHGZLWK JURZWKPHGLXP LQFOXGLQJ
F\FORKH[LPLGH IRU ± KRXUV 5LSD 	0nUGK  ,QIHFWHG FHOOV GHYHORS
LQWUDF\WRSODVPLF LQFOXVLRQV ZKLFK DUH GHWHFWHG E\ VWDLQLQJ ZLWK ÀXRUHVFHLQ
conjugated antibodies against chlamydial antigens such as MOMP or LPS. 
Until the introduction of NAATs, cell culture was the most sensitive method for 
detecting C. trachomatis, but now cell culture is usually used as a diagnostic test for 
C. trachomatisRQO\ZKHQ1$$7VDUHQRWDYDLODEOHRUDɣRUGDEOH&HOOFXOWXUHLVYHU\
VSHFL¿FEXWWKHVHQVLWLYLW\LVDSSUR[LPDWHO\±FRPSDUHGWRWKHFRPPHUFLDOO\
available NAATs (Meyer 2016). In addition, cell culture is non-standardised, 
technically complex, labour intensive and expensive, and the specimen collection 
and transport are critical. However, the capacity to culture C. trachomatis should 
be maintained at least in some centralised laboratories to support surveillance and 
research, for example when new variants emerge.
2.10.2 NUCLEIC ACID AMPLIFICATION TESTS
At present NAATs are recommended for the laboratory diagnosis of C. trachomatis 
LQIHFWLRQV/DQMRXZHWDO3DSSHWDO7KHVHWHVWVDUHH[WUHPHO\VSHFL¿F
DQGVHQVLWLYHHQRXJKWRGHWHFWVPDOOTXDQWLWLHVRIFKODP\GLDOQXFOHLFDFLG$VWKHVH
tests do not detect viable organisms, transport and storage conditions are not critical. 
7KHXVHRI¿UVWYRLGXULQH)98DQGXUHWKUDOFHUYLFDODQGYDJLQDOVZDEVKDYH
been validated by the manufacturers of NAATs. Extragenital specimens, such as 
pharyngeal and rectal swabs, are cleared by the Food and Drug Administration 
(FDA) for two commercially available C. trachomatis NAATs (Aptima Combo 2 
Assay, Hologic, Marlborough, MA, USA and Xpert Ct/NG, Cepheid, Sunnyvale, CA, 
86$)RUVHYHUDORWKHU1$$7VVXɤFLHQWHYLGHQFHVXSSRUWVWKHXVHRIWKHVHWHVWVLQ
the detection of C. trachomatis at extragenital sites (Lanjouw et al. 2016; Papp et al. 
2014). In addition, home-based self-collection for C. trachomatis testing has been 
DFFHSWHGZLWKFRPSDUDEOHVHQVLWLYLW\DQGVSHFL¿FLW\WRFOLQLFLDQFROOHFWHGVSHFLPHQV
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(Fajardo-Bernal et al. 2015). In Finland, home-based sampling is provided by some 
laboratories in the public and private sector. The self-obtained FVU and vaginal 
swab samples are sent via mail to the laboratory, and the results are sent to the 
patient by a short message service. 
Five NAAT assay platforms are FDA-cleared for the detection of C. trachomatis: 
$EERWW5HDO7LPH&71*$EERWW0ROHFXODU'HV3ODLQHV,/86$$SWLPD&RPER
2/Aptima CT assays, BD ProbeTec assay (Becton Dickinson, Eysins, Switzerland), 
&REDV&71*WHVW5RFKH'LDJQRVWLFV*PE+0DQQKHLP*HUPDQ\DQG;SHUW&7
NG assay (Papp et al. 2014) (Table 3). These technologies amplify chlamydial plasmid 
'1$FKURPRVRPDO'1$RUU51$ZLWKPHWKRGVEDVHGRQ3&5WUDQVFULSWLRQ
PHGLDWHGDPSOL¿FDWLRQ70$RUVWUDQGGLVSODFHPHQWDPSOL¿FDWLRQ6'$7KH
$EERWWDQG5RFKH1$$7VDOVRKDYHGXDOWDUJHWVIRUC. trachomatis. Targeting the 
FKODP\GLDOSODVPLGRUU51$UHVXOWV LQ LQFUHDVHGVHQVLWLYLW\RIWKHWHVWDVWKHVH
targets are present in multiple copies in the bacterium compared to the single copy 
of the chlamydial genome (Chernesky et al. 2014). In addition, these NAATs are 
often combined with the detection of another STI pathogen, Neisseria gonorrhoeae.
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Table 3. The nucleic acid targets and amplification methods of the five major manufacturers of C. trachomatis 
NAATs.
NAAT Target Method Manufacturer
Abbott RealTime CT/NG plasmid DNA 
(two targets)
PCR Abbott Molecular
Aptima Combo 2 assay 23S rRNA TMA Hologic
Aptima CT assay 16S rRNA TMA Hologic
BD ProbeTec ET CT/GC assay plasmid DNA SDA Becton Dickinson
Cobas CT/NG test chromosomal and 
plasmid DNA
PCR Roche
Xpert CT/NG assay chromosomal DNA PCR Cepheid
NAAT, nucleic acid amplification test; PCR, polymerase chain reaction; TMA, 
transcription mediated amplification; SDA, strand displacement amplification.
 
The commercial NAATs used to detect C. trachomatis are highly sensitive and 
VSHFL¿FEXWGRQRWGLɣHUHQWLDWHEHWZHHQJHQRW\SHV)RUGHWHFWLQJWKHC. trachomatis 
LGV types, there are commercial genital ulcer multiplex NAATs available, but these 
tests are not evaluated in the context of rectal LGV infections (de Vries et al. 2019). 
/*9JHQRW\SHVDUHPDLQO\LGHQWL¿HGXVLQJLQKRXVH3&5WHVWVWDUJHWLQJHLWKHUWKH
ompA or pmpH genes in centralised laboratories (Morré et al. 2008).
2.10.3 SEROLOGY
In the European guideline or in the recommendation by Centers for Disease Control 
and Prevention, USA, serology is not recommended for the diagnosis of acute 
uncomplicated C. trachomatis infections, because anti-chlamydial antibodies are 
detectable several weeks after initial infection or may not develop at all (Lanjouw 
et al. 2016; Papp et al. 2014). In addition, serological tests are not as sensitive and 
VSHFL¿FDV1$$7VDQGFDQQRWGLɣHUHQWLDWHEHWZHHQSDVWDQGFXUUHQW LQIHFWLRQ
However, serology might have some value in the diagnosis of ascending infections 
and reactive arthritis, and in infertility work-up (Lanjouw et al. 2016). In these cases, 
C. trachomatis can be undetectable in the urogenital specimens and serological 
data may be used to evaluate the role of C. trachomatis in the infection. Serological 
assays can represent an alternative method for the diagnosis for LGV, especially 
ZKHQ/*9VSHFL¿FWHVWVDUHQRWDYDLODEOHGH9ULHVHWDO$KLJKDQWLERG\
titre, especially anti-MOMP immunoglobulin (Ig) A antibodies, in a patient with 
symptoms suggestive of an LGV infection supports the diagnosis. However, a 
low titre does not exclude LGV, nor does a high titre in a patient without LGV 
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V\PSWRPRORJ\FRQ¿UP/*9LQIHFWLRQ&KODP\GLDODQWLERGLHVFDQEHGHWHFWHGZLWK
FRPSOHPHQW¿[DWLRQDQG0,)WHVWV,QDGGLWLRQHQ]\PHLPPXQRDVVD\V(,$
immunoblots or line assays are currently used in C. trachomatis serology (Meyer 
1RYHOELRPDUNHUVIRUPRUHVSHFL¿FVHURORJ\DUHEHLQJGHYHORSHG5DQWVL
et al. 2019).
2.10.4 POINT-OF-CARE TESTS
C. trachomatis NAATs are usually performed in large, centralised laboratories 
ZKLFKUHTXLUHVWUDQVSRUWDWLRQRIVDPSOHVDQGUHSRUWLQJWKHWHVWUHVXOWVEDFNWRWKH
clinicians. Therefore, with NAAT-based diagnostics, the patients need to come back 
to the clinic for the results. This can lead to delayed treatment or no treatment at all 
if the patients do not return and further transmit the infection. This has led to the 
development of point-of-care tests (POCT) (Kelly et al. 2017). The currently available, 
PRVWO\LPPXQRFKURPDWRJUDSKLF32&7VDUHEDVHGRQODWHUDOÀRZWHFKQRORJ\DQG
detect Chlamydia LPS antigen in genital swabs or urine. Unfortunately, these tests 
have poor sensitivity compared to NAATs and therefore are not suitable to be used as 
a screening test for C. trachomatis infection (van Dommelen et al. 2010). Other tests 
EDVHGRQDQWLJHQGHWHFWLRQDUHDOVRDYDLODEOHVXFKDV(,$VDQGGLUHFWÀXRUHVFHQW
antibody tests, but NAATs are approximately 20–35% more sensitive than these 
tests and their use in routine diagnostics is not recommended (Papp et al. 2014).
7KH&HSKHLG;SHUW&71*DVVD\ZDVWKH¿UVWFRPPHUFLDOUDSLG1$$7WKDW
provided point-of-care testing for C. trachomatis and N. gonorrhoeae in 90 minutes 
(Gaydos et al. 2013). New, more rapid tests based on nucleic acid detection are 
currently being developed as not all patients are willing to wait for 90 minutes for 
WKHUHVXOWV7KHVHUDSLGVHQVLWLYHDQGDɣRUGDEOH32&7VDUHGHVSHUDWHO\QHHGHG
especially in low-resource and remote areas (Kelly et al. 2017). 
2.10.5 TESTING GUIDELINES
The recommended specimens for the diagnosis of urogenital C. trachomatis 
infections with NAATs are FVU in men and a self- or clinician-collected vaginal 
swab in women (Lanjouw et al. 2016; Papp et al. 2014). In men, a urethral swab 
VDPSOHLVHTXLYDOHQWWRDXULQHVDPSOHLQGHWHFWLQJC. trachomatis, but clearly more 
invasive. In women, cervical samples taken during a pelvic examination are also 
appropriate, but vaginal swabs have proved to be as sensitive as cervical samples in 
NAATs. Due to decreased sensitivity, FVU is not the recommended specimen type 
for women. Annual C. trachomatis testing is recommended for all sexually active 
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young women and men under 25 years of age, and repeated testing in 3–6 months 
VKRXOGEHRɣHUHGWRWKRVH\RXQJLQGLYLGXDOVZKRWHVWSRVLWLYHIRUC. trachomatis 
(Lanjouw et al. 2016; Workowski & Bolan 2015). International guidelines do not 
encourage a test-of-cure (TOC) to be routinely performed unless adherence in 
WKHUDS\ LVTXHVWLRQHGV\PSWRPVSHUVLVWRUUHLQIHFWLRQ LVVXVSHFWHG+RZHYHU
the Finnish national treatment guideline recommends a TOC four weeks after the 
WUHDWPHQW&ROODERUDWRUV7KLV LV WKHRQO\GLɣHUHQFHEHWZHHQWKH)LQQLVK
DQGWKH LQWHUQDWLRQDOJXLGHOLQHV5RXWLQHDQQXDOVFUHHQLQJRIH[WUDJHQLWDOVLWHV
including rectum and pharynx is recommended for MSM (Workowski & Bolan 
2015), but such recommendations are not available for women or heterosexual 
men, although extragenital infections among these individuals are not uncommon 
(Chan et al. 2016).
A current European guideline on the management of LGV recommends that 
LGV should be tested in all MSM with a C. trachomatis positive anorectal sample, 
FRQWDFWV RI FRQ¿UPHG/*9 LQGH[ FDVHV SDWLHQWVZLWK V\PSWRPV VXVSHFWHG RI
having LGV, HIV-positive MSM and MSM using anti-HIV medication (de Vries 
et al. 2019). Other C. trachomatis positive sites (urethra, urine or pharynx) can be 
tested for LGV if symptoms persist despite antibiotic treatment. A two-test procedure 
LV UHFRPPHQGHG¿UVWDFRPPHUFLDO1$$7IRUGHWHFWLQJC. trachomatis and a 
second in-house NAAT for detecting LGV types (de Vries et al. 2019; Papp et al. 
2014). However, the sensitivities of the various in-house NAATs are generally lower 
compared to the sensitivities of the commercial NAATs. LGV routine molecular 
diagnostics should be available in all countries and it can be centralised at a national 
reference laboratory.
2.10.6 VARIANTS EVADING DETECTION
In southwest Sweden, Halland county, an unexpected fall of 25% in C. trachomatis 
cases was observed in 2005–2006, even though the number of patients tested 
KDG UHPDLQHG VLPLODU FRPSDUHG WR WKH\HDUEHIRUH 5LSD	1LOVVRQ ,Q
6ZHGHQFRPPHUFLDO1$$7VIURP$EERWWDQG5RFKHZHUHXVHGLQWKHGHWHFWLRQRI
C. trachomatis, which at that time detected the cryptic plasmid of C. trachomatis. 
A subset of samples (n=1700) was analysed with another commercial NAAT Artus 
$5786+DPEXUJ*HUPDQ\WKDWWDUJHWVWKHC. trachomatis ompA gene, and 
13% of the samples were found positive with the Artus test only. Selected strains 
ZHUHVHTXHQFHGDQGWKHQY&7ZDVIRXQGZLWKDEDVHSDLUESGHOHWLRQLQWKH
25)RIWKHSODVPLG5LSD	1LOVVRQ$OOWKHVWUDLQVZHUHRIJHQRW\SH(
The deletion involved the entire target area in the Abbott test and a major part of 
WKHWDUJHWDUHDLQWKH5RFKHWHVW,QWKH6ZHGLVKFRXQWLHVZKHUHWHVWVIURP$EERWW
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DQG5RFKHZHUHXVHGWKHQY&7FRPSULVHG±RIWKHC. trachomatis cases 
(Herrmann 2007). In the counties that used the Becton Dickinson test, with the 
target area residing outside the deletion in the plasmid, the nvCT comprised 7–20% 
of the C. trachomatisFDVHV+HUUPDQQ5HWURVSHFWLYHDQDO\VLVVKRZHGWKDW
the nvCT was present already in 2003, and it has been estimated that there were 
15 000 missed C. trachomatis cases caused by the failing detection of the nvCT 
(Jurstrand et al. 2013). Until 2008, it was not known if the nvCT had also spread 
to Finland.
Another C. trachomatisYDULDQWZDV LGHQWL¿HGLQ)LQODQGLQ)HEUXDU\
$ GLVFUHSDQF\ LQ UHVXOWV REWDLQHG ZLWK WZR GLɣHUHQW 1$$7V XVHG WR GHWHFW 
C. trachomatis was observed in the Clinical Microbiology Laboratory of Turku 
8QLYHUVLW\+RVSLWDO5DQWDNRNNR-DODYDHWDO$Q)98VDPSOHIURPDSDWLHQW
was positive for C. trachomatis with the Allplex STI Essential test (Seegene, Seoul, 
Korea), and a urethral swab specimen taken on the same day was negative for 
C. trachomatisZLWKWKH$SWLPD&RPERWHVWZKLFKWDUJHWVFKODP\GLDO6U51$
/DWHUWKHVDPHVDPSOHVZHUHFRQ¿UPHGWREHSRVLWLYHIRUC. trachomatis with the 
$SWLPD&7WHVWZKLFKGHWHFWV6U51$6HTXHQFLQJRIWKHVHOHFWHGVWUDLQVUHYHDOHG
DQXFOHRWLGHVXEVWLWXWLRQLQWKHU51$JHQHLQSRVLWLRQ&WR7ZKLFKLV
not present in any of the C. trachomatisUHIHUHQFHVWUDLQVHTXHQFHVGHSRVLWHGLQ
the GenBank. The strains were all of genotype E. It was estimated that in 2019 
more than 200 C. trachomatis cases were missed due to the Finnish new variant of 
C. trachomatis ),QY&7JHQHUDWLQJIDOVHQHJDWLYHHTXLYRFDO$SWLPD&RPER
results (Hokynar et al. 2019). However, no decrease in the number of C. trachomatis 
FDVHVQRWL¿HGE\ ODERUDWRULHVZDV REVHUYHG LQ)LQODQG LQ±2XWVLGH
Finland, two cases of FI-nvCT were detected in Örebro county, Sweden (Unemo 
et al. 2019), and 81 C. trachomatisFDVHVGXHWRWKH),QY&7ZHUH LGHQWL¿HGLQ
Norway (Johansen et al. 2019). Just when the FI-nvCT emerged is uncertain: the 
earliest available specimen that contained the FI-nvCT was taken in Turku in June 
2018 (Hokynar et al. 2019). 
2.11 TREATMENT OF C. TRACHOMATIS INFECTIONS
The international and Finnish national treatment guidelines recommend 
doxycycline 100 mg twice a day orally for seven days or azithromycin 1 g single oral 
dose in the treatment of uncomplicated urogenital C. trachomatis infections and 
C. trachomatis conjunctivitis (Collaborators 2018; Lanjouw et al. 2016; Workowski 
& Bolan 2015). The cure rates with these two regimens are similar and exceed 95% 
(Geisler et al. 2015). For uncomplicated non-LGV rectal and pharyngeal infections, 
the recommendation is the same as for urogenital infections, although doxycycline is 
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preferred to azithromycin in treating rectal infections. If azithromycin is used to treat 
rectal infections, a TOC should be taken. Higher cure rates of rectal C. trachomatis 
infections have been observed with doxycycline compared to azithromycin (Kong 
et al. 2015). 
The recommended treatment for both symptomatic and asymptomatic LGV 
infections is doxycycline 100 mg twice a day orally for 21 days suggested by 
international and Finnish national guidelines (Collaborators 2018; de Vries et al. 
2019; Workowski & Bolan 2015). Alternative antibiotic therapy is erythromycin 500 
PJIRXUWLPHVDGD\RUDOO\IRUGD\V,IVSHFL¿FWHVWVIRU/*9DUHQRWDYDLODEOH
patients suspected of having LGV should be treated empirically with doxycycline 
for three weeks. 
Chlamydia can develop resistance to antibiotics through point mutations in 
vitro and these mutations can be passed on to other strains through horizontal 
JHQHWUDQVIHUDQGKRPRORJRXVUHFRPELQDWLRQ6DQGR]	5RFNH\+RZHYHU
there is no evidence of any stable genetic or phenotypic antimicrobial resistance 
in C. trachomatisKDPSHULQJWUHDWPHQWLQFOLQLFDOVHWWLQJV+DG¿HOGHWDO
6DQGR]	5RFNH\$IHZFOLQLFDOWUHDWPHQWIDLOXUHVZLWKD]LWKURP\FLQJ
single oral dose have been described (Geisler et al. 2015), but they are more likely 
explained by reinfection, poor compliance or tolerance to treatment, or detection 
of non-viable C. trachomatis with NAATs from a TOC sample taken too early, than 
by the existence of antimicrobial resistance.
2.12. CONTROL OF C. TRACHOMATIS INFECTIONS
2.12.1 SCREENING
The goal of the C. trachomatis infection control is to prevent the development of 
DGYHUVHVHTXHODHVXFKDV3,'HFWRSLFSUHJQDQF\DQG7),E\LGHQWLI\LQJDQGWUHDWLQJ
the infected individuals. Control strategies against STIs such as C. trachomatis 
LQIHFWLRQVLQFOXGHVFUHHQLQJZLWKKLJKO\VHQVLWLYHDQGVSHFL¿FGHWHFWLRQPHWKRGV
DQWLELRWLFWUHDWPHQWRISDWLHQWVDFFRUGLQJWRWUHDWPHQWJXLGHOLQHVHɤFLHQWFRQWDFW
WUDFLQJQRWL¿FDWLRQDQG WUHDWPHQWKHDOWKSURPRWLRQDGYLFH DQG IROORZXSRI
patients (Lanjouw et al. 2016). 
7KH HɣHFW RI VFUHHQLQJ LQ WKH UHGXFWLRQ RI SUHYDOHQFH DQG LQFLGHQFH RI 
C. trachomatis infections and reproductive complications has been analysed, 
and the results have been contradictory. A systematic review and meta-analysis 
evaluated randomised controlled trials of C. trachomatis screening and concluded 
WKDWWKHHɣHFWRIVFUHHQLQJZDVORZLQUHGXFLQJWKHSUHYDOHQFHDQGLQFLGHQFHRI 
C. trachomatis LQIHFWLRQV/RZHWDO7KLVREVHUYDWLRQZDVFRQ¿UPHGLQ
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a recent cluster-randomised controlled trial performed in Australia (Hocking et 
al. 2018). However, a large-scale population testing was successful in reducing 
C. trachomatis prevalence and declining the average duration of infection in 
(QJODQG DOWKRXJK WKLV HɣHFWZDV ODWHUSDUWO\ UHYHUVHG /HZLV	:KLWH
Similarly in Finland, a population-based C. trachomatis screening trial resulted 
LQDVLJQL¿FDQWUHGXFWLRQRISUHYDOHQFHIURPWRDPRQJ\RXQJZRPHQ
(Lehtinen et al. 2018). C. trachomatis VFUHHQLQJ HɣRUWV PD\ KDYH DW OHDVW D
PRGHUDWHHɣHFW LQSUHYHQWLQJC. trachomatis DVVRFLDWHG VHTXHODHPDLQO\3,'
(Low et al. 2016). Indeed, the declining rates in reproductive complications have 
EHHQZLWQHVVHGLQVHYHUDOFRXQWULHV/\\WLNlLQHQHWDO5HNDUWHWDO
7KLVGDWDRQWKHHɣHFWRIVFUHHQLQJLQWKHUHGXFWLRQRISUHYDOHQFHDQGLQFLGHQFHRI 
C. trachomatisLQIHFWLRQVDQGVHTXHODHKDYHSURPSWHGWRHQKDQFHWKHPDQDJHPHQW
of C. trachomatis LQIHFWLRQVDQGGLVHDVHZLWKHɣRUWV LQHɤFLHQWSDWLHQWFRQWURO
counselling and education, alongside with C. trachomatis screening (Unemo et 
al. 2017). 
The surveillance of C. trachomatis infections is an important part of the 
C. trachomatis infection control which should be executed both at the national 
and international levels. In Finland, C. trachomatis LQIHFWLRQV DUHQRWL¿HGE\
ODERUDWRULHVDQG/*9LQIHFWLRQVDUHQRWL¿HGE\FOLQLFLDQVWRWKH1,'5PDLQWDLQHG
by the Finnish Institute for Health and Welfare according to the Communicable 
'LVHDVHV$FW1,'5LVDSXEOLFO\RSHQGDWDEDVHDYDLODEOHRQWKHLQWHUQHW,Q(XURSH
the ECDC, and globally the World Health Organization contribute to the surveillance 
of communicable diseases including C. trachomatis and publish reports on the 
incidence and prevalence of C. trachomatis infections. In addition, monitoring 
the rates of clinically diagnosed PID, ectopic pregnancy and TFI is important in 
DVVHVVLQJWKHHɣHFWVRIWKHQDWLRQDOC. trachomatis infection control measures.
2.12.2 VACCINE
As the screening and treatment of C. trachomatis infections might not result in 
DVLJQL¿FDQWUHGXFWLRQLQ LQFLGHQFHDQGSUHYDOHQFHRWKHUFRQWUROVWUDWHJLHVDUH
needed. Ultimately, the development of a C. trachomatis vaccine is needed for 
the permanent decline of prevalence rates. A successful vaccine must trigger the 
T cell-mediated immune response in the genital mucosa. C. trachomatis vaccine 
development has been challenged by the poor understanding of the immune response 
in the female genital tract, the lack of adjuvants that target vaccines to the genital 
PXFRVDWKHSRRUNQRZOHGJHRIWKHVSHFL¿FDQWLJHQVWKDWLQGXFHDSURWHFWLYHLPPXQH
response, and the lack of tools to genetically manipulate C. trachomatis (Brunham 
	5H\/DGLQR7KH¿UVWKXPDQYDFFLQHWULDOVLQYROYHGWKHDGPLQLVWUDWLRQRI
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whole inactivated EBs which led to partial short-lived protection but aggravated the 
symptoms of reinfections in some individuals (Grayston & Wang 1978). Thereafter, 
the research focus has been in the development of recombinant subunit vaccines 
that are based on individual C. trachomatis protein antigens, and the selection of 
a suitable adjuvant and delivery system. 
'HVSLWHWKHUHVHDUFKHɣRUWVOLFHQVHGC. trachomatis vaccines are not available. 
5HFHQWO\DJHQLWDOChlamydia vaccine candidate entered phase one human clinical 
WULDO IRUWKH¿UVWWLPH$EUDKDPHWDO7KHUHFRPELQDQWYDFFLQHLQFOXGHV
DQWLJHQ&7+ZKLFK LV FRPSRVHGRI VHJPHQWVRI WKH0203IURPGLɣHUHQW
genotypes adjuvanted with either CAF01 liposomes or aluminium hydroxide. 
These vaccines, administered both intramuscularly and intranasally, were safe 
and tolerated, and induced anti-CTH522 IgG seroconversion and cell-mediated 
immune responses in the participants. This holds promise for the development of 
DQHɤFLHQWC. trachomatis vaccine.
2.13. OTHER SEXUALLY TRANSMITTED MICROBES
A C. trachomatis co-infection with other sexually transmitted pathogens is common 
5RZOH\ HW DO  67,V LQFOXGLQJC. trachomatis increase the risk of HIV 
DFTXLVLWLRQDQGWUDQVPLVVLRQ*DOYLQ	&RKHQ,QFUHDVHGVXVFHSWLELOLW\WR
HIV might be due to mucosal disruption and the recruitment of leucocytes, especially 
the target cells of HIV CD4+ T cells to the endocervix. C. trachomatis also increases 
HIV shedding in the genital tract. 
Sexually transmitted genital herpes caused by an HSV1 or HSV2 infection is 
extremely common with 544 million cases annually (Looker, Magaret, May, et al. 
2015; Looker, Magaret, Turner, et al. 2015). The global prevalence estimate for a 
genital HSV infection was 15% (18% in women and 12% in men) in 2012. After 
the initial infection, HSV establishes lifelong latency during which the viral gene 
expression is limited and no symptoms occur (Jaishankar & Shukla 2016). Upon 
reactivation infectious viral particles and viral DNA are shed, and clinical disease 
can recur producing genital ulcers.
HHV-6 might also be sexually transmitted as it is shed in the genital tract of 
ZRPHQ/HDFKHWDO++9QRZLQFOXGHVWZRGLɣHUHQWYLUXVHV++9$DQG
++9%ZLWKGLɣHUHQWHSLGHPLRORJLFDODQGELRORJLFDOFKDUDFWHULVWLFVDQGGLVHDVH
associations (Ablashi et al. 2014). Although less is known about the epidemiology 
RI++9$++9% LV D XELTXLWRXV YLUXV++9% LQIHFWLRQ XVXDOO\ RFFXUV
early in childhood and can cause fever and rash (exanthema subitum) (Agut et 
al. 2015). HHV-6 infections including primary infections and reactivation can be 
asymptomatic. The seroprevalence of HHV-6 among adults is approximately 98% 
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(Ward et al. 1993). HHV-6 can integrate into the host telomeres, and less than 1% of 
individuals have HHV-6 DNA in their chromosomes (Agut et al. 2015). In addition 
to the possible sexual transmission, HHV-6 is known to be vertically transmitted 
from mother to infant and through saliva (Agut et al. 2015). 
Genital HPV infections are extremely common, and the disease burden associated 
with HPV is enormous with 12% worldwide prevalence in women with normal 
cervical cytology (Forman et al. 2012). Many HPV infections clear spontaneously, 
but especially infections caused by the high-risk HPV genotypes can lead to cervical 
cancer, one of the leading cancers in women worldwide (Joura et al. 2014). Sero-
HSLGHPLRORJLFDQG3&5EDVHGVWXGLHVVXJJHVWWKDWC. trachomatis, together with 
HPV, increases the risk of development of cervical dysplasia, which can progress to 
cervical cancer (Castellsagué et al. 2014; Lehtinen et al. 2011). The exact mechanisms 
of infection on the development of precancerous lesions are not known, but 
C. trachomatis possesses several mechanisms to modulate the host cell signalling 
SDWKZD\VLQGXFH'1$GDPDJHLQKLELWDSRSWRVLVDQGLQGXFHFKURQLFLQÀDPPDWLRQ
(Gagnaire et al. 2017). The HPV vaccination programmes implemented in several 
high-income countries have succeeded in declining the infectious load of HPV and 
preventing HPV-related outcomes (Gottlieb & Johnston 2017).
M. genitalium is an emerging sexually transmitted pathogen, which is strongly 
associated with non-gonococcal and non-chlamydial urethritis in men (Taylor-
5RELQVRQ	-HQVHQ,QZRPHQM. genitalium can cause urethritis, cervicitis, 
HQGRPHWULWLVDQG3,'7KHLQFUHDVLQJPDFUROLGHDQGÀXRURTXLQRORQHUHVLVWDQFHRI
M. genitalium is problematic since these two groups of antibiotics are virtually the 
only options to treat M. genitaliumLQIHFWLRQV8QHPR	-HQVHQ5HVLVWDQFH
WRPDFUROLGHVLVGXHWR613VLQWKH6U51$JHQHRIM. genitalium, and mutations 
in the DNA gyrase and topoisomerase IV genes leading to amino acid changes 
FRQIHU UHVLVWDQFH WRÀXRURTXLQRORQHV LQM. genitalium. N. gonorrhoeae is the 
second most common bacterium causing sexually transmitted infections, with an 
HVWLPDWHGPLOOLRQJRQRUUKRHDFDVHVRFFXUULQJDQQXDOO\5RZOH\HWDO
Like M. genitalium, N. gonorrhoeae has developed resistance against virtually all 
antimicrobials used in the treatment of gonorrhoea (Unemo & Jensen 2017). The 
widespread use of the macrolide azithromycin in the treatment of C. trachomatis 
infections has most probably contributed to the resistance in M. genitalium and 
N. gonorrhoeae (Unemo & Jensen 2017).
In Finland, C. trachomatis and N. gonorrhoeae infections are reported to the 
1,'5+69+39DQG M. genitaliumLQIHFWLRQVDUHQRWQRWL¿DEOHGLVHDVHVLQ)LQODQG
and the prevalence rates of infections caused by these microbes are not known. 
In addition, the prevalence of HHV-6 in the genital tract has not been reported 
in Finland.
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3. AIMS OF THE STUDY
3. AIMS OF THE STUDY
This study aimed to determine the ompA genotype distribution of C. trachomatis, 
and the prevalence of C. trachomatis LGV types, the Swedish nvCT, and urogenital 
HSV, HHV-6, HPV and M. genitalium in Finland. Another aim was to study the 
transcriptional expression of the selected C. trachomatis genes during in vitro and 
in vivo infections.
The detailed aims of the individual studies were:
i. To determine the ompA genotype distribution of C. trachomatis and to 
investigate the occurrence of the Swedish nvCT among urogenital samples 
in Finland. 
ii. To set up an LGV genotyping method suitable for a diagnostic laboratory using 
NAATs in the detection of C. trachomatis, to investigate the prevalence of 
C. trachomatis LGV types and to determine the ompA genotype distribution 
of C. trachomatis among rectal and pharyngeal samples in Finland.
iii. To study the expression of the C. trachomatis ompA, cpaf, tarp and tox genes 
during in vitro infection in a cervical epithelial cell line, using low-passage-
number clinical isolates. Another aim was to evaluate the expression of the 
same genes in vivo in cervical swab specimens collected from patients with a 
C. trachomatis infection.
iv. To determine the prevalence rates of HSV, HHV-6, HPV and M. genitalium, 
and mutations leading to macrolide resistance in M. genitalium in 
C. trachomatis positive and C. trachomatis negative urogenital samples among 
young women in Finland. Another aim was to study whether co-infections or 
the C. trachomatisJHQRW\SHDɣHFWWKHFOHDUDQFHRIC. trachomatis.
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4. MATERIALS AND METHODS
4.1 CLINICAL SAMPLES (I, II, III, IV)
The material for the C. trachomatis ompA genotyping included 160 unselected 
C. trachomatis NAAT positive samples from women and men sent for 
C. trachomatis, or C. trachomatis and N. gonorrhoeae testing at HUSLAB, 
Helsinki, Finland in 2008 (I). The 160 samples included FVUs (n=82), cervical/
vaginal swabs (n=75) and conjunctival swabs (n=3). The samples were collected 
with the Aptima Urine Specimen Collection Kit for Male and Female Urine 
Specimens or with the Aptima Unisex Specimen Collection Kit for Endocervical 
and Male Urethral Swab Specimens, and were tested with the Aptima Combo 2 
Assay (Hologic, Marlborough, MA, USA) (n=84). The samples collected with the 
$PSOLFRU&71*6SHFLPHQ3UHSDUDWLRQ.LWZHUHWHVWHGZLWKWKH&REDV7DT0DQ
&77HVW5RFKH'LDJQRVWLFV*PE+0DQQKHLP*HUPDQ\Q 
The occurrence of the Swedish nvCT was analysed in 495 urogenital 
samples from women and men sent for C. trachomatis, or C. trachomatis and 
N. gonorrhoeae testing at HUSLAB, Helsinki, Finland in 2008 (I). The 414 samples 
were C. trachomatis NAAT positive with the Aptima Combo 2 Assay (Hologic). 
The 55 samples were C. trachomatis1$$7SRVLWLYHZLWK WKH&REDV7DT0DQ
&77HVWY5RFKH'LDJQRVWLFVDEOHWRGHWHFWWKHQY&7DQGVDPSOHVZHUH 
C. trachomatis 1$$7 QHJDWLYH ZLWK WKH &REDV 7DT0DQ &7 7HVW 5RFKH
Diagnostics) unable to detect the nvCT.
For the detection of the C. trachomatis LGV types, we included 140 
C. trachomatis NAAT positive extragenital samples sent for C. trachomatis and 
N. gonorrhoeae testing at HUSLAB, Helsinki, Finland with the Aptima Combo 
2 Assay (Hologic) in 2009–2011 (II). The material consisted of 84 rectal (70 
from men and 14 from women) and 56 pharyngeal swabs (27 from men and 
29 from women) collected with the Aptima Unisex Specimen Collection Kit for 
Endocervical and Male Urethral Swab Specimens (Hologic).
The study for the transcriptional expression of C. trachomatis included 127 
cervical swab samples obtained from patients who attended the outpatient STI 
clinic of Helsinki University Hospital, Helsinki, Finland in 2009–2011 because 
RIV\PSWRPV IRU IROORZXSRUEHFDXVHRIQRWL¿FDWLRQE\DQ LQIHFWHGSDUWQHU
(III). The samples collected with the Aptima Unisex Specimen Collection Kit 
for Endocervical and Male Urethral Swab Specimens (Hologic) were tested for 
C. trachomatis and N. gonorrhoeae with the Aptima Combo 2 Assay (Hologic) 
at HUSLAB, Helsinki, Finland. The cervical samples collected in Universal 
Transport Medium (UTM, Copan, Brescia, Italy) were used for the culture of 
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C. trachomatis. Of the 127 samples, 50 were C. trachomatis NAAT positive 
and 77 were C. trachomatis NAAT negative. The in vivo C. trachomatis gene 
expression analysis was performed with the 44 cervical swabs available. The 
in vitro transcriptional expression of C. trachomatis ZDVDQDO\VHGLQ¿YHORZ
SDVVDJHQXPEHUSDVVDJHFOLQLFDO LVRODWHVUHSUHVHQWLQJWKHPRVWFRPPRQ
genotypes E and F (E127, E129, E142, F175 and F213) in urogenital samples.
The prevalence of HSV, HHV-6, HPV, M. genitalium, and mutations leading to 
macrolide resistance in M. genitalium was investigated in 314 urogenital samples 
from 157 C. trachomatis NAAT positive women, and their age-, location- and 
time-matched 157 C. trachomatis NAAT negative controls participating in an 
HPV vaccination trial and simultaneously in a C. trachomatis screening trial 
in 2010–2017 (IV). The self-collected vaginal swab samples rinsed in FVU 
collected with the Abbott multi-Collect Specimen Collection Kit were analysed 
for C. trachomatis and N. gonorrhoeaeZLWKWKH$EERWW5HDO7LPH&71*DVVD\
(Abbott Molecular) at Fimlab Laboratories, Tampere, Finland. All women with 
a C. trachomatis NAAT positive sample were invited to give a TOC sample one 
month later. The urogenital samples had previously been analysed for HPV DNA 
DWWKH'HSDUWPHQWRI&OLQLFDO0LFURELRORJ\6NnQH8QLYHUVLW\+RVSLWDO0DOP|
6ZHGHQ6|GHUOXQG6WUDQGHWDO6|GHUOXQG6WUDQG	'LOOQHU
The collection of the clinical samples was approved by the Independent 
,QVWLWXWLRQDO5HYLHZ%RDUGRI WKH+RVSLWDO'LVWULFWRI+HOVLQNLDQG8XVLPDD
(18.2.2009 HUSLAB §19/2009, 15.6.2009 HUSLAB §44/2009, 16.2.2012 
HUSLAB §18/2012, 10.1.2013 HUSLAB §2/2013, 11.4.2014 HUSLAB §13/2014, 
17.3.2015 HUSLAB §7/2015) (I, II & III), the Ethics Committee of the Department 
of Medicine, Hospital District of Helsinki and Uusimaa (5.6.2009 §241/2009, 
,,,	,,,DQGWKH(WKLFDO5HYLHZ
Board of the North Ostrobothnia Hospital District (19.11.2012; §295/2012) (IV). 
A written informed consent was obtained from the patients (III & IV). A summary 
of all the clinical samples and the analyses performed in studies I–IV is presented 
in Table 4.
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Table 4. The clinical samples and the analyses performed in studies I–IV.
Study Samples
(n)
Sample type Collection 
year
Ctr NAAT 
result
Analysis method
I
160
FVU, cervical/
vaginal and 
conjunctival swabs
2008 160 positives Ctr ompA PCR
495 FVU, cervical/vaginal swab 2008
469 positives 
26 negatives
Swedish nvCT PCR, 
plasmid sequencing
II 140 rectal and pharyngeal swabs 2009–2011 140 positives
Ctr pmpH PCR,
Ctr ompA PCR and 
ompA sequencing
III 127 cervical swab 2009–2011 50 positives77 negatives
Ctr culture in 
McCoy, 
Ctr infection in 
HeLa229, Ctr cpaf, 
tarp, tox and ompA 
RT-PCRs
IV 314 urogenital 2010–2017 157 positives157 negatives
M. genitalium, 
M. genitalium 
macrolide 
resistance, HSV, 
HHV-6 and Ctr 
ompA PCRs
Ctr, Chlamydia trachomatis; NAAT, nucleic acid amplification test; FVU, first-void 
urine; ompA, major outer membrane protein gene; PCR, polymerase chain reactions; 
nvCT, new variant of C. trachomatis; pmpH, polymorphic membrane protein H gene; 
cpaf, chlamydial protease-like activity factor; tarp, translocated actin-recruiting 
phosphoprotein gene; tox, chlamydial cytotoxin gene; RT-PCR, reverse transcriptase-
PCR; HSV, herpes simplex virus; HHV-6, human herpesvirus 6
4.2 CELL LINES (I, II, III, IV)
The McCoy cells (from Pekka Saikku, University of Oulu, Finland) were maintained 
in BKH-21 medium supplemented with 10% fetal calf serum, 2 mM glutamine and 
20 PJPOJHQWDPLFLQLQDKXPLGL¿HGLQFXEDWRUZLWK&22 at 35 °C (I, II, III & IV).
The HeLa229 cells (CCL-2.1) from the American Type Culture Collection (ATCC, 
Manassas, VA, USA) were maintained in ɲͲDD (Sigma-Aldrich, Darmstadt, 
Germany) supplemented with 10% fetal calf serum, 2 mM glutamine (GlutaMax, 
*LEFR7KHUPR)LVKHU6FLHQWL¿F:DOWKDP0$86$Pg/ml gentamicin and 
JOXFRVHLQDKXPLGL¿HGLQFXEDWRUZLWK&22 at 35 °C (III).
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4.3 C. TRACHOMATIS INFECTION OF THE MCCOY AND 
HELA229 CELLS (I, II, III, IV)
The McCoy cells in 24-well plates were infected and centrifuged at 3000 x g at 
30 °C for one hour (I, II, III, IV). BHK-21 medium supplemented with 10% fetal 
calf serum, 2 mM glutamine, 20 Pg/ml gentamicin, 50 U/ml nystatin, 100 Pg/ml 
vancomycin, and 0.5 Pg/ml cycloheximide was added, and the plates were incubated 
in 5% CO2 at 35 °C for 48 hours. After incubation, the cells were collected in sucrose-
phosphate-glutamate, pH 7.2, and slowly frozen to -70 °C.
The HeLa229 cells in 24-well plates were infected at a multiplicity of infection 
of 1.0 (III). The plates were centrifuged at 3000 x g at 30 °C for one hour and 
incubated in 5% CO2 at 35 °&IRURQHKRXUĮ0(06LJPD$OGULFKVXSSOHPHQWHG
with 10% fetal calf serum, 2 mM glutamine (GlutaMax, Gibco, Thermo Fisher 
6FLHQWL¿FPg/ml gentamicin, 0.5% glucose, 50 U/ml nystatin and 0.5 Pg/ml 
cycloheximide was added, and the plates were incubated in 5% CO2 at 35 °C for 
2, 6, 12, 24 and 48 hours. After incubation, the cells were collected in ice-cold 
SKRVSKDWHEXɣHUHGVDOLQH
4.4 IMMUNOFLUORESCENCE MICROSCOPY (I, III)
'LUHFW LPPXQRÀXRUHVFHQFHVWDLQLQJZDVSHUIRUPHGRQC. trachomatis infected 
FHOOFXOWXUHVZLWKD3DWK¿QGHUChlamydia&XOWXUH&RQ¿UPDWLRQ6\VWHP%LR5DG
Hercules, CA, USA).
4.5 C. TRACHOMATIS ISOLATES AND REFERENCE STRAINS (I, 
II, III, IV)
6WXG\,,, LQFOXGHGORZSDVVDJHQXPEHUSDVVDJHC. trachomatis clinical 
isolates propagated in McCoy cells. In addition, C. trachomatis reference strains 
W\SHV$±.DQG/$7&&QXPEHUV$95%%95&95'95
(95%)95*95+95,95-95.95DQG
/95SURSDJDWHGLQ0F&R\FHOOVZHUHXVHG,,,,,,	,9
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4.6 AMPLIFICATION AND QUANTIFICATION CONTROLS FOR 
REAL-TIME PCR (I, II, III, IV)
7KHVHTXHQFHÀDQNLQJWKHGHOHWLRQVLWHLQWKHSODVPLGRIWKH6ZHGLVKQY&7ZDV
FORQHGLQWRDS&5%OXQW,,7232YHFWRUZLWKWKH,QYLWURJHQ=HUR%OXQW72323&5
&ORQLQJ.LW7KHUPR)LVKHU6FLHQWL¿FWRVHUYHDVDQDPSOL¿FDWLRQFRQWUROLQWKH
6ZHGLVKQY&73&5,7KHVDPSOHFRQWDLQLQJWKH6ZHGLVKQY&7ZDVDJLIWIURP
%M|UQ+HUUPDQQ8QLYHUVLW\RI8SSVDOD6ZHGHQ7RTXDQWLI\WKHC. trachomatis 
JHQRPHHTXLYDOHQWV*(VGXULQJ+H/DFHOO LQIHFWLRQDS,'760$57$03
plasmid containing the C. trachomatis type E ompA3&5WDUJHWVHTXHQFHZDV
purchased from Integrated DNA Technologies (Coralville, IA, USA) (III). As an 
DPSOL¿FDWLRQFRQWURO IRU+69++9DQGM. genitalium3&5WKH3&5WDUJHW
VHTXHQFHVLQDS,'760$57$03SODVPLGZHUHSXUFKDVHGIURP,QWHJUDWHG'1$
Technologies (IV). DNA extracted from C. trachomatis reference strain types A–K 
DQG/$7&&SURSDJDWHGLQ0F&R\FHOOVZDVXVHGDVDQDPSOL¿FDWLRQFRQWUROLQ
WKH3&5DQDO\VHV,,,,,,,9
4.7 NUCLEIC ACID EXTRACTION AND CDNA SYNTHESIS (I, II, 
III, IV)
DNA was extracted from a sample volume of 400 Pl of urogenital sample with 
D0DJ1$3XUH&RPSDFWLQVWUXPHQW5RFKH0ROHFXODU6\VWHPV3OHDVDQWRQ&$
USA) using a MagNA Pure Compact Nucleic Acid Isolation Kit I and eluted in 50 
Pl (I for ompA3&5,,'1$ZDVH[WUDFWHGIURPDVDPSOHYROXPHRIPl of 
XURJHQLWDOVDPSOHZLWKD0DJ1$3XUH/&LQVWUXPHQW5RFKH0ROHFXODU6\VWHPV
using a MagNA Pure LC DNA Isolation Kit I and eluted in 100 PO,IRUQY&73&5
Plasmid DNA was extracted with a QIAprep Spin Miniprep Kit (Qiagen, Hilden, 
Germany) (I). DNA was extracted from 100 or 200 Pl of C. trachomatis infected 
McCoy cells with a DNeasy blood and tissue kit (Qiagen) and eluted in 200 Pl (III). 
DNA was extracted from 250 Pl of C. trachomatis infected HeLa229 cells with a 
3XUH/LQN*HQRPLF'1$.LW7KHUPR)LVKHU6FLHQWL¿FDQGHOXWHGLQPl (III). 
DNA was extracted from a sample volume of 500 Pl of urogenital sample with a 
0DJ1$3XUH/&6\VWHP5RFKH0ROHFXODU6\VWHPVXVLQJD0DJ1$3XUH/&
DNA Isolation Kit-Large Volume and eluted in 100 Pl (IV).
51$ZDVH[WUDFWHGIURPORIC. trachomatis infected HeLa229 cells stored 
LQ51$ODWHU6ROXWLRQ7KHUPR)LVKHU6FLHQWL¿FZLWKDQ51$TXHRXV3&5.LW
7KHUPR)LVKHU6FLHQWL¿FDQGWUHDWHGZLWKGHR[\ULERQXFOHDVHXVLQJD785%2
'1$IUHH.LW7KHUPR)LVKHU6FLHQWL¿F,,,51$ZDVH[WUDFWHGIURPWKHFHUYLFDO
VDPSOHVZLWKDQ51$TXHRXV3&5.LW7KHUPR)LVKHU6FLHQWL¿FDQGHOXWHGLQ
O,,,
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'1$ DQG 51$ FRQFHQWUDWLRQV ZHUH PHDVXUHG ZLWK D 1DQR'URS 
VSHFWURSKRWRPHWHU7KHUPR)LVKHU6FLHQWL¿F'1$ZDVVWRUHGLQ°C or -70 
°&DQG51$ZDVVWRUHGLQ°C until analysis (I, II, III).
&RPSOHPHQWDU\'1$F'1$ZDVV\QWKHVLVHGXVLQJWKH51$H[WUDFWHGIURP
infected HeLa229 cells and cervical samples with a Maxima First Strand cDNA 
6\QWKHVLV.LWIRU57T3&57KHUPR)LVKHU6FLHQWL¿F,,,
4.8 DETECTION OF NUCLEIC ACIDS (I, II, III, IV)
For the C. trachomatis ompA genotyping, two primer sets and eleven genotype-
VSHFL¿FSUREHV IRU W\SHV'±.DQG/±/ZHUHXVHGZLWKDPHWKRGGHVFULEHG
previously (Jalal et al. 2007) (I). For detecting the Swedish nvCT, primers and a 
SUREHÀDQNLQJWKHGHOHWLRQVHTXHQFHLQWKHFU\SWLFSODVPLGRIC. trachomatis were 
XVHGHPSOR\LQJDPHWKRGGHYHORSHGHDUOLHU&DWVEXUJHWDO,%RWK3&5V
contained 250 nM primers and 100 nM probes.
A previously described method was used to detect the C. trachomatis LGV types 
&KHQHWDOEDVHGRQDEDVHSDLUGHOHWLRQLQWKHVHTXHQFHRIWKHpmpH 
gene, which is present only in LGV strains (Stothard et al. 2003) (II). The method 
included primers and two probes for detecting both LGV (L1–L3) and non-LGV 
'±.W\SHV7KH3&5VFRQWDLQHGQ0SULPHUVDQGQ0SUREHV
The primers and probes for the detection of the C. trachomatis cpaf, tarp and 
tox genes were designed with the Primer Express software v3.0 (Applied Biosystems, 
7KHUPR)LVKHU6FLHQWL¿FEDVHGRQWKHC. trachomatisFRPSOHWHJHQRPHVHTXHQFHV
LQWKH1&%,5HIHUHQFH6HTXHQFH'DWDEDVH7DEOH,,,7KHSULPHUVDQGSUREHV
ZHUHWHVWHGIRUVSHFL¿FLW\ZLWKWKH1&%,¶VEDVLFORFDODOLJQPHQWVHDUFKWRRO%/$67
(https://blast.ncbi.nlm.nih.gov/) and with C. trachomatis reference strains. The 
3&5IRUcpaf contained 600 nM primers and 200 nM probes, for tarpWKH3&5
contained 300 nM primers and 200 nM probes, and for toxWKH3&5FRQWDLQHG
nM primers and 100 nM probes. The ompA3&5ZDVSHUIRUPHGZLWKDPHWKRG
designed earlier and contained 250 nM primers and 100 nM probes (Jalal et al. 
2006). Each time after infection the raw ompA, cpaf, tarp and tox3&5DPSOL¿FDWLRQ
data were normalised against the number of C. trachomatis GEs in each sample, 
determined with the ompA3&5%RUJHVHWDO
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Table 5. Sequences of the C. trachomatis cpaf, tarp and tox primers and probes (III).
Ctr 
target 
gene
Amplicon 
length 
(bp)
Primer/probe sequence (5´–3´)
cpaf 86
forward TAGGATGGGATCTTGTTCAAAGCT
reverse CTGCTGGCAAAAACTTGTTGAT
probe 6-FAM-CTGCACAGCAGAAGCTTCGTACACAAGAA-BHQ-1
tarp 108
forward CCTCTTCTGGAGATGATTCAGGAA
reverse TACGCACGGCAGAAAGGATA
probe 6-FAM-CCTCTGTCGGAAATGACGGACCTGCT-BHQ-1
tox 106
forward GATTCTTTAATTTCTGCTTGCTGAAA
reverse TGTTCGATCTCCTCAGTAGGAAGTTT
probe 6-FAM-CTCGGCAATATCAATGACGAAACGCGT-BHQ-1
Ctr, Chlamydia trachomatis; bp, base pairs; cpaf, chlamydial protease-like activity factor; 
FAM, fluorescein amidite; BHQ, black hole quencher; tarp, translocated actin-recruiting 
phosphoprotein gene; tox, chlamydial cytotoxin gene 
7KH3&5VIRUWKHGHWHFWLRQRI+69+69DQG+69'1$SRO\PHUDVHJHQH
(Pillet et al. 2015), HHV-6 (HHV-6A and HHV-6B U67 gene) (Karlsson et al. 2012), 
M. genitalium (adhesin gene) (Jensen et al. 2004), M. genitalium macrolide 
UHVLVWDQFHPXWDWLRQV LQWKH6U51$JHQH1XPPLHWDODQGKXPDQ
EHWDJORELQJHQH1XPPLHWDOZHUHGHYHORSHGSUHYLRXVO\,97KH3&5
IRU+69FRQWDLQHGQ0SULPHUVDQG Q0SUREHV IRU++9 WKH3&5
contained 100 nM forward primers, 600 nM reverse primers and 200 nM probes, 
for M. genitalium WKH3&5FRQWDLQHGQ0SULPHUVDQGQ0SUREHV IRU 
M. genitaliumPDFUROLGHUHVLVWDQFHWKH3&5FRQWDLQHGQ0IRUZDUGSULPHUV
Q0UHYHUVHSULPHUVDQGQ0SUREHVDQGIRUEHWDJORELQWKH3&5FRQWDLQHG
200 nM primers and 100 nM probes.
&5%ZHUHGHWHFWHGZLWK3DQChlamydiales 3&5 /LHQDUG HW DO ZLWK
modifications (Hokynar et al. 2016). Pan-Chlamydiales 3&5 DPSOLILHV DQ
DSSUR[LPDWHO\ESIUDJPHQWRIWKH6U51$JHQHDQGGHWHFWVDZLGHUDQJHRI
GLɣHUHQWPHPEHUVRIWKHChlamydialesRUGHU7KH3&5FRQWDLQHGQ0SULPHUV
and 100 nM probes.
The primers and probes were purchased from Applied Biosystems (Thermo 
)LVKHU 6FLHQWL¿F ,QWHJUDWHG '1$ 7HFKQRORJLHV0HWDELRQ ,QWHUQDWLRQDO $*
2OLJRPHUDQG7$*&RSHQKDJHQ$67KH3&5VZHUHSHUIRUPHGLQDPl volume 
containing 12.5 PO0D[LPD3UREHT3&50DVWHU0L[7KHUPR)LVKHU6FLHQWL¿F
3ODWLQXP4XDQWLWDWLYH3&56XSHU0L[8'*,QYLWURJHQ7KHUPR)LVKHU6FLHQWL¿F
52
 0$7(5,$/6$1'0(7+2'6
RU7DT0DQ8QLYHUVDO0DVWHU0L[$SSOLHG%LRV\VWHPV7KHUPR)LVKHU6FLHQWL¿F
5HDOWLPH3&5DQDO\VHVZHUHSHUIRUPHGZLWKDQ$%,LQVWUXPHQWDQG6HTXHQFH
'HWHFWLRQ6RIWZDUHY$SSOLHG%LRV\VWHPV7KHUPR)LVKHU6FLHQWL¿FRU5RWRU
Gene 6000 (Qiagen). The thermal cycling conditions were two minutes at 50 °C, ten 
minutes at 95 °C, 40 or 45 cycles of 15 seconds at 95 °C, and one minute at 60 °C.
4.9 DNA SEQUENCING (I, II)
The samples containing the Swedish nvCT and the C. trachomatis L2 type were 
VHTXHQFHGDWWKH%LRPHGLFXP6HTXHQFLQJ8QLW)DFXOW\RI0HGLFLQH8QLYHUVLW\RI
+HOVLQNL)LQODQG)RUWKH6ZHGLVKQY&71&%,¶V3ULPHU%/$67KWWSZZZQFEL
QOPQLKJRYWRROVSULPHUEODVWZDVXVHGWRGHVLJQVHTXHQFLQJSULPHUVIRUWKH
UHJLRQÀDQNLQJWKHGHOHWLRQVLWHRIWKHYDULDQWSODVPLGEDVHGRQWKHVHTXHQFHRIWKH
plasmid (GenBank no. EF121575) (I). The part of the C. trachomatis ompA gene 
LQFOXGLQJWKHQXFOHRWLGHPLVPDWFKHVEHWZHHQWKHGLɣHUHQW/W\SHV//DDQG
/E6SDDUJDUHQ)HQQHPDHWDORIWKH/SRVLWLYHVDPSOHVZDVVHTXHQFHG
ZLWKSULPHUV3DQG3-DODOHWDO,,6HTXHQFLQJRIWKH3&5SURGXFWVZDV
SHUIRUPHGLQERWKGLUHFWLRQV7KHVHTXHQFHVZHUHDQDO\VHGZLWK6HTXHQFH6FDQQHU
6RIWZDUHY$SSOLHG%LRV\VWHPV7KHUPR)LVKHU6FLHQWL¿FDQGFRPSDUHGWRWKH
VHTXHQFHGDWDEDVHZLWK1&%,¶V1XFOHRWLGH%/$67
4.10 STATISTICAL ANALYSIS (IV)
The pYDOXHVZHUHFDOFXODWHGZLWKWKH)LVKHU¶VH[DFWWHVWXVLQJWKH,%063666WDWLVWLFV
v24 (IBM, Armonk, NY, USA). A p-value less than 0.05 was considered statistically 
VLJQL¿FDQW7KHFRQ¿GHQFHLQWHUYDOVZHUHDOVRFDOFXODWHG/DQH
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5. RESULTS 
5.1 C. TRACHOMATIS OMPA GENOTYPE DISTRIBUTION IN  
THE UROGENITAL SAMPLES (I, III, IV)
Of the 160 C. trachomatis NAAT positive urogenital samples collected and analysed 
in 2008, 144 (90%) could be genotyped with the ompA3&5XVLQJJHQRW\SHVSHFL¿F
probes for types D–K (I) (Table 7). The genotype distribution was: E 40% (n=57), 
F 28% (n=41), G 13% (n=19), D 8% (n=11), K 5% (n=7), H 3% (n=5), J/Ja 2% (n=3), 
I/Ia 0% (n=0) and D-F mixed infection 1% (n=1). The 16 samples that remained 
negative for genotypes D–K were analysed for genotypes L1–L3. We did not detect 
any L types among these urogenital samples. The remaining 16 (10%) samples most 
probably did not include enough DNA to be genotyped.
We were able to culture C. trachomatis from 40 (80%) cervical samples from 
50 C. trachomatis NAAT positive patients collected in 2009–2011 (III). The 
C. trachomatis ompA genotype distribution of the isolates was E 40% (n=16), 
F 20% (N=8), G 13% (n=5), D 10% (n=4), K 10% (n=4), B 5% (n=2) and H 2.5% 
Q 2XUJHQRW\SLQJUHVXOWVKDYHEHHQFRQ¿UPHGZLWK:*6DQGWKHGDWDKDYH
EHHQVXEPLWWHGWRWKH(1$+DG¿HOGHWDO
Of the C. trachomatis NAAT positive urogenital samples collected in 2010–2017 
from 166 infection episodes of 157 women, 146 (88%) samples could be genotyped 
and 20 (12%) samples were non-typeable (IV). The genotype distribution was 
E 47% (n=69), F 27% (n=39), G 9% (n=13), K 8% (n=11), D 5% (n=8), H 3% (n=4) 
and J 1% (n=2). The genotype distributions from studies I, III and IV are presented 
in Table 9 in Discussion.
5.2 PREVALENCE OF THE C. TRACHOMATIS LGV TYPES AND 
THE OMPA GENOTYPE DISTRIBUTION IN THE EXTRAGENITAL 
SAMPLES (II)
Of the 140 C. trachomatis NAAT positive rectal and pharyngeal samples collected 
in 2009–2011, 114 (81%) samples (85% of the rectal and 77% of the pharyngeal 
swabs) could be genotyped as LGV (L1–L3) and non-LGV (D–K) types with the 
pmpH3&57DEOH7KHUHPDLQLQJVDPSOHVZHUHQRQW\SHDEOHXVLQJWKLV
PHWKRGPRVWSUREDEO\GXHWRWKHORZTXDQWLW\RIFKODP\GLDO'1$LQWKHVDPSOHV
Non-LGV types were detected in 104 (91%) samples, LGV types were detected in 
nine (8%) samples and one sample (1%) contained both non-LGV and LGV types. 
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LGV types were detected in nine rectal swabs and one pharyngeal swab. One patient 
had LGV types both at the rectal and the pharyngeal sites, so altogether nine LGV 
'1$SRVLWLYHSDWLHQWVZHUHLGHQWL¿HG
Table 6. The non-LGV and LGV types detected in rectal and pharyngeal samples with the pmpH PCR
Genotype Rectal samples
n (%)
Pharyngeal samples
n (%)
All samples
n (%)
Non-LGV 62 (87) 42 (98) 104 (91)
LGV 8 (11) 1 (2) 9 (8)
Non-LGV & LGV 1 (1) 0 (0) 1 (1)
Total 71 (100) 43 (100) 114 (100)
LGV, lymphogranuloma venereum; pmpH, polymorphic membrane protein H gene; PCR, 
polymerase chain reaction
The 140 C. trachomatis NAAT positive extragenital samples were genotyped with 
the ompA3&52IWKHVDPSOHVRIWKHUHFWDODQGRIWKH
pharyngeal swabs) could be genotyped and 36 (26%) remained without a genotype 
(Table 7). All the samples positive for LGV with the pmpH3&5ZHUHRIJHQRW\SH
L2 with the ompA3&5,QWKHUHFWDOVZDEVRI060JHQRW\SHV*'(DQG/
ZHUHPRVWIUHTXHQWO\GHWHFWHGZKLOHLQKHWHURVH[XDOZRPHQ(DQG'ZHUHWKHPRVW
IUHTXHQWJHQRW\SHV,QWKHSKDU\QJHDOVDPSOHVJHQRW\SHV(DQG'ZHUHWKHPRVW
detected in men, and genotypes E and F in women. In addition, the ompA gene 
RIWKHVDPSOHVSRVLWLYHIRUJHQRW\SH/ZDVVHTXHQFHG:HLGHQWL¿HGVL[VDPSOHV
with genotype L2b and two samples with genotype L2. Because of an L2-J mixed 
LQIHFWLRQRQHVDPSOHFRXOGQRWEHVHTXHQFHG
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Table 7. The C. trachomatis ompA genotype distribution of rectal and pharyngeal samples in men and 
women (II), and the genotype distribution of urogenital samples (I).
Study II (2009–2011) Study I (2008)
Men Women Men and women
Genotype Rectum n (%)
Pharynx 
n (%)
Rectum 
n (%)
Pharynx 
n (%)
Urogenital 
n (%)
E 8 (16) 10 (53) 5 (45) 10 (40) 57 (40)
F 0 (0) 1 (5) 1 (9) 5 (20) 41 (28)
G 15 (31) 1 (5) 0 (0) 3 (12) 19 (13)
D 13 (27) 6 (32) 2 (18) 1 (4) 11 (8)
K 0 (0) 0 (0) 0 (0) 1 (4) 7 (5)
H 0 (0) 0 (0) 1 (9) 2 (8) 5 (3)
J 3 (6) 0 (0) 0 (0) 1 (4) 3 (2)
I 1 (2) 0 (0) 1 (9) 0 (0) 0 (0)
L2 8 (16) 1 (5) 0 (0) 0 (0) 0 (0)
Mixed 1 (2) 0 (0) 1 (9) 2 (8) 1 (1)
Total 49 19 11 25 144 
1LQH/*9SRVLWLYHSDWLHQWVZHUHLGHQWL¿HG7KHPHDQDJHRIWKHSDWLHQWVZDV
(range 22–52), all patients were MSM, and all except one were HIV positive. Other 
STIs, including syphilis (4/9), gonorrhoea (3/9) and HCV (1/9) were detected among 
these patients. Five of the nine patients reported sexual contacts outside Finland 
in other European countries, and several of the patients had had more than ten 
sexual partners during the last 12 months. C. trachomatis was not detected in the 
FVUs or urethral samples of these patients taken at the same visit as the rectal 
swab. Two of the patients also had a C. trachomatis positive pharyngeal swab. 
One of the pharyngeal swabs contained the same genotype L2, the other could not 
be genotyped. 
5.3 PREVALENCE OF THE SWEDISH NEW VARIANT OF  
C. TRACHOMATIS IN THE UROGENITAL SAMPLES (I)
Of the 469 urogenital samples screened for the Swedish nvCT, two samples (0.4%) 
ZHUHLGHQWL¿HGZLWKWKHYDULDQWSODVPLG7KHVDPSOHVZHUHIURPWZRIHPDOHSDWLHQWV
RQHZDV)98DQGWKHRWKHUZDVDYDJLQDOVZDEVDPSOH6HTXHQFLQJFRQ¿UPHGWKDW
the C. trachomatisLQWKHVDPSOHVKDUERXUHGWKHYDULDQWSODVPLGDVWKHVHTXHQFH
ÀDQNLQJWKHGHOHWLRQUHJLRQLQWKH25)ZDVLGHQWLFDOWRWKDWRIWKH6ZHGLVKQY&7
5LSD	1LOVVRQ%RWKQY&7VZHUHRIJHQRW\SH(DVKDVEHHQUHSRUWHGLQ
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other countries (Dahlberg et al. 2018). The samples were originally tested positive 
with the Aptima Combo 2 Assay (Hologic) that can detect the Swedish nvCT as the 
WHVWWDUJHWV6U51$RIC. trachomatis.
5.4 PREVALENCE OF HSV, HHV-6, HPV AND MYCOPLASMA 
GENITALIUM IN THE UROGENITAL SAMPLES (IV)
The prevalence of HSV, HHV-6, HPV and M. genitalium was analysed in the 
urogenital samples of 314 young women (157 C. trachomatis NAAT positive women 
and their 157 C. trachomatis1$$7QHJDWLYHFRQWUROV+39'1$ZDVIUHTXHQWO\
GHWHFWHGLQWKHXURJHQLWDOVDPSOHVDQGPRUHIUHTXHQWO\GHWHFWHGDPRQJ
the C. trachomatis positives than among the negatives (66% vs. 25%, p<0.001) 
(Table 8). HSV DNA was present in 1% of the samples, HHV-6 DNA in 12% of the 
samples, and M. genitalium DNA in 3.2% of the samples. Of the ten samples positive 
for M. genitalium DNA, two samples (20%) contained a mutation associated with 
macrolide resistance. A slightly higher prevalence of M. genitalium (4.5% vs. 1.9%) 
and HSV DNA (1.9% vs. 0%) in the C. trachomatis positive samples was observed, 
EXWWKHVHGLɣHUHQFHVZHUHQRWVWDWLVWLFDOO\VLJQL¿FDQW$PRQJWKHVSHFLPHQV
22 (21 among C. trachomatis NAAT positive and one among C. trachomatis NAAT 
negative) were positive for three of the microbes analysed. Only one sample was 
positive for N. gonorrhoeae.
Among the 157 C. trachomatis NAAT positive women, 166 infection episodes 
were evaluated, as nine women had two C. trachomatis infection episodes during the 
study period. A TOC sample was taken approximately one month after the treatment 
with a single 1 g dose of azithromycin, and it was available from 121 (73%) women. 
The infection episodes were divided into infection not cleared (C. trachomatis TOC 
positive, n=16) and infection cleared (C. trachomatis TOC negative, n=105) based 
on the C. trachomatis NAAT result of the TOC sample. Of the 121 TOC samples, 
sixteen (13%) were positive for C. trachomatis. A TOC sample was not available 
from 45 (27%) women. The prevalence of HSV, HPV and M. genitalium was similar 
between those who cleared the C. trachomatis infection and those who did not 
7DEOH++9'1$ZDVVOLJKWO\PRUHIUHTXHQWO\GHWHFWHGDPRQJWKRVHZKR
gave a C. trachomatis SRVLWLYH72&VDPSOH YV EXW WKLVGLɣHUHQFH
GLGQRWUHDFKVWDWLVWLFDOVLJQL¿FDQFH1RGLɣHUHQFHVZHUHREVHUYHGEHWZHHQWKH 
C. trachomatis ompA genotype distributions of those who cleared the infection 
and those who did not.
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Table 8. The prevalence (% and 95% confidence interval) of HSV, HHV-6, HPV and M. genitalium DNA in 
the urogenital samples of 157 C. trachomatis NAAT positive and 157 NAAT negative women, and in the 
samples of women who gave a C. trachomatis test-of-cure (TOC) positive (n=16) and a TOC negative 
(n=105) negative sample. 
HSV HHV-6 HPV M. genitalium
Ctr positive 
(n=157)
3 
(1.9%; 0–4.3%)
17 
(11%; 5.6–16.0%)
104 
(66%; 58.5–73.9%)
7 
(4.5%; 1.0–8.0%)
Ctr negative 
(n=157)
0
(0%)
22 
(14%; 8.3–19.7%)
39 
(25%; 17.7–31.9%)
3 
(1.9%; 0–4.3%)
p-value1 0.248 0.494 <0.001 0.336
Total (n=314) 3 (1.0%) 39 (12%) 143 (46%) 10 (3.2%)
TOC positive 
(n=16)
0 
(0%)
3 
(19%; 0–41.1%)
9 
(56%; 28.9–83.7%)
0 
(0%)
TOC negative 
(n=105)
1 
(1.0%; 0–3.4%)
10 
(10%; 3.4–15.6%)
75 
(71%; 62.4–80.5%)
5 
(4.8%)
p-value1 1.000 0.377 0.250 1.000
HSV, herpes simplex virus; HHV-6, human herpesvirus 6; HPV, human papillomavirus; 
Ctr, Chlamydia trachomatis; TOC, test-of-cure; 1 Fisher’s exact test was used to calculate 
the statistical significance.
5.5 PREVALENCE OF CHLAMYDIA-RELATED BACTERIA IN THE 
UROGENITAL SAMPLES
The C. trachomatis NAAT negative urogenital samples from study IV (n=157) 
and 82 additional C. trachomatis NAAT negative urogenital samples from the 
C. trachomatisVFUHHQLQJWULDOZHUHDQDO\VHGIRU&5%ZLWKWKH3DQChlamydiales 
3&57KLV3&5GHWHFWVDOOPHPEHUVRIWKHChlamydiales order, so we could clearly 
not analyse the samples positive for C. trachomatis.7KHDPSOLFRQV IURP3&5
SRVLWLYHUHDFWLRQVZHUHVHTXHQFHGDQGDQDO\VHGZLWK%/$67WRYHULI\ WKH3&5
¿QGLQJVDQGWRFODVVLI\WKHGHWHFWHG&5%2IWKHVDPSOHVDQDO\VHGRQO\WZR
FRQWDLQHG&5%'1$+RN\QDUHWDOXQSXEOLVKHGUHVXOWV7KH¿UVWVDPSOH
contained a member of Parachlamydiaceae which was highly similar (97%) to the 
&5%VHTXHQFHVGHWHFWHGLQIxodes ricinus ticks (Pilloux et al. 2015). The second 
VDPSOHFRQWDLQHGD&5%UHVHPEOLQJWKRVHGHWHFWHGLQQDVRSKDU\QJHDOVDPSOHV
of hospitalised children in Switzerland (Lienard et al. 2011). W. chondrophila has 
a sero-epidemiological association with miscarriage (Baud et al. 2014), but this 
bacterium was not detected among the samples from young women.
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5.6 EXPRESSION OF THE C. TRACHOMATIS OMPA, CPAF, TARP 
AND TOX GENES (III)
5.6.1 GENE EXPRESSION OF C. TRACHOMATIS IN THE CERVICAL SWABS
The in vivo expression of the C. trachomatis ompA, cpaf, tarp and tox genes was 
¿UVWDQDO\VHGLQWKHFHUYLFDOVZDEV$PRQJWKHC. trachomatis NAAT positive 
VDPSOHVDYDLODEOHIRUDQDO\VLVVPDOODPRXQWVRIPHVVHQJHUULERQXFOHLFDFLGP51$
of one or several of the investigated genes were observed in nine samples: ompA 
P51$LQ¿YHcpafP51$LQ¿YHtarpP51$LQWKUHHDQGtoxP51$LQWKUHH
samples. Among the eight C. trachomatis1$$7QHJDWLYHVDPSOHVQRVXFKP51$
was detected.
5.6.2 GROWTH OF C. TRACHOMATIS CLINICAL ISOLATES AND REFERENCE 
STRAINS
7KH +H/D FHOO FXOWXUHV ZHUH LQIHFWHG ZLWK WKH ¿YH ORZSDVVDJHQXPEHU 
C. trachomatis clinical isolates (E127, E129, E142, F175 and F213) representing the 
most common genotypes E and F and the C. trachomatis reference strains type 
E and F. The number of C. trachomatis GEs was determined with the ompA3&5
at 2, 6, 12, 24 and 48 hpi. The results are based on two biological replicates, and 
the experiment was performed twice with similar results. The exponential period 
of growth in the reference strains E and F was observed at 12–36 hpi (Figure 4). 
In the clinical isolates, the exponential period of growth took place at 12–24 hpi in 
E127, at 12–36 hpi in E142, F213 and F175, and at 24–36 hpi in E129. 
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Figure 4. Growth kinetics of C. trachomatis reference strain E (CtrE) and clinical 
isolates E127, E129 and E142 (left panel), and C. trachomatis reference strain F and 
clinical isolates F213 and F175 (right panel) in HeLa229 cells at 2, 6, 12, 24 and 48 
hours post infection determined with the major outer membrane protein gene (ompA) 
PCR. The results are shown as relative genome equivalents (GEs), the number of GEs 
at 2 hpi was set as one. The results are based on two biological replicates, and the 
experiment was performed twice with similar results.
The generation times were calculated by comparing the number of GEs at the 
beginning and the end of the exponential growth phase of C. trachomatis. We 
observed a doubling time of 2.8 h for C. trachomatis reference strain type E, a 
doubling time of 2.9 h for reference strain type F, and a doubling time of 2.2 h for 
the clinical isolate E127. The doubling times were longer (E129 4.3 h, E142 4.0 h, 
F213 3.6 h and F175 4.3 h) in the other clinical isolates. All clinical isolates, except 
one (E127), exhibited a slower growth rate than the reference strains.
After the lag phase (6–12 hpi) of the chlamydial developmental cycle, we observed 
a 2200-fold increase in the number of C. trachomatis GEs in the C. trachomatis 
reference strain type E and a 790-fold increase in GEs in the reference strain type 
F. For the clinical isolates, the increase was more modest, with an 11–190-fold 
increase in types E, and a 90–180-fold increase in types F. The reference strain 
W\SHV(DQG)ZHUHPRUHHɤFLHQWLQSURGXFLQJSURJHQ\WKDQWKHFOLQLFDOLVRODWHV
5.6.3 GENE EXPRESSION OF C. TRACHOMATIS IN THE HELA229 CELLS
The expression of the C. trachomatis ompA, cpaf, tarp and tox genes was studied 
LQ+H/DFHOOVLQIHFWHGZLWKWKH¿YHORZSDVVDJHQXPEHUFOLQLFDOLVRODWHV(
E129, E142, F175 and F213) and the reference strains type E and F at 2, 6, 12, 24, 36 
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and 48 hpi. The results are based on two biological replicates, and the experiment 
was performed twice with similar results.
The C. trachomatis ompA was expressed between 12 and 48 hpi, and the peak 
of the expression was observed at 24 hpi in the reference strains and the clinical 
isolates (Figure 5). Among the reference strains and the clinical isolate E127, the 
ompA expression was high already at 12 hpi compared with the other clinical isolates. 
The expression of cpaf peaked at 12 hpi in the clinical isolate E127, and at 24 hpi in 
the other clinical isolates and the reference strains. In addition, the cpaf expression 
in the reference strain type E was high at 6, 12 and 24 hpi and in the reference 
strain type F at 24 hpi, compared to the clinical isolates. The chlamydial tarp was 
expressed between 24 and 48 hpi and the peak of expression was between 36 and 
48 hpi among all clinical isolates and the reference strains. The expression of tox 
was observed between 12 and 48 hpi, and the peak of expression was at 12 hpi 
for the reference strains and the clinical isolate E127, and at 24 hpi for the other 
clinical isolates. 
Figure 5. The expression of the C. trachomatis major outer membrane protein (ompA), the chlamydial 
protease-like activity factor (cpaf), the translocated actin-recruiting phosphoprotein (tarp) and the 
chlamydial cytotoxin (tox) genes of the reference strains E (CtrE) and F (CtrF), and the clinical isolates 
E127, E129, E142, F213 and F175 in the HeLa229 cells at 2, 6, 12, 24 and 48 hours post infection. At each 
timepoint, raw ompA, cpaf, tarp and tox PCR amplification data were normalised against the number of 
C. trachomatis genome equivalents (GEs) in each sample (Borges et al. 2010). The results are based on 
two biological replicates, and the experiment was performed twice with similar results.
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6.1. C. TRACHOMATIS OMPA GENOTYPE DISTRIBUTION  
(I, II, III, IV)
Before study I, the Finnish C. trachomatis ompA genotype distribution among 
urogenital samples was analysed in 1987 (Saikku & Wang 1987) and 1996 (Penttilä et 
DO:KHQWKHGLVWULEXWLRQRIWKHGLɣHUHQWJHQRW\SHVIURPVWXG\,LVFRPSDUHG
to those from 1987 and 1996, the proportion of genotypes F and G seems to have 
increased, whereas the proportion of genotypes D and E seems to have remained 
fairly stable (Table 9). However, diverse typing methods were used in these studies: 
monoclonal antibodies in 1987, ompA3&5DQG5)/3LQDQGompA3&5DQG
JHQRW\SHVSHFL¿FSUREHVLQVWXG\,,WLVRILQWHUHVWWKDWDVLPLODUFKDQJHZDVREVHUYHG
with a method based on monoclonal antibodies in Seattle, USA: the proportion 
of infections due to serovars F and G increased in 1988–1996 (Suchland et al. 
2003). When the genotype distribution from studies I, III and IV was compared, 
WKHSURSRUWLRQRIJHQRW\SHVKDVUHPDLQHGTXLWHVWDEOHLQ)LQODQGGXULQJWKHODVWWHQ
years. This observation can be considered reliable, as the same method was used 
IRUJHQRW\SLQJDOWKRXJKWKHVSHFLPHQFROOHFWLRQVGLɣHUHGLQWKHVHVWXGLHV6WXGLHV
I and III included samples collected at the Helsinki and Uusimaa region, while in 
study IV the samples were collected in several communities across Finland. The 
ompA genotype distribution seems to be similar throughout Finland.
When the Finnish ompA genotype distribution in study I is compared to those 
reported in other countries, the proportion of genotypes is fairly similar in Finland, 
Sweden (Lysén et al. 2004), the Netherlands (Spaargaren et al. 2004) and Portugal 
(Nunes et al. 2009). In contrast, the proportion of genotypes E and G seems slightly 
higher in Europe than in the USA, while the proportions of genotype J/Ja and I/
Ia tend to be somewhat higher in the USA than in Europe (Millman et al. 2004). 
The typing methods used in these studies varied which might explain the observed 
GLɣHUHQFHV+RZHYHUZKHQVWXGLHVXVLQJGDWDSURGXFHGZLWKompA3&5DQG
VHTXHQFLQJDUHFRPSDUHG/\VpQHWDO0LOOPDQHWDO1XQHVHWDO
2009), the observations remain. 
7KHUHLVFRQÀLFWLQJHYLGHQFHRQWKHFRQQHFWLRQRIWKHGLɣHUHQWompA genotypes 
to the clinical manifestations of C. trachomatis infections. Some studies found no 
association between genotype and disease phenotype (Lysén et al. 2004; Persson 
& Osser 1993). However, other studies linked genotypes F and/or G to abdominal 
pain, symptomatic severe endometrial disease or PID (Dean et al. 1995; Gao et 
al. 2007; Geisler et al. 2003; Millman et al. 2006; van Duynhoven et al. 1998). In 
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addition, genotype E was associated with asymptomatic infections (Dean et al. 1995; 
*DRHWDO6WXUP5DPLUH]HWDO,ILQIHFWLRQVFDXVHGE\JHQRW\SH(
show fewer symptoms than infections due to the other genotypes, C. trachomatis 
genotype E might be able to spread without being detected, which could explain 
the high proportion of infections caused by this genotype. The opposing results in 
the studies might be due to the small number of cases investigated, confounding 
IDFWRUVVXFKDVDJHDQGUDFHODFNRIVSHFL¿FGLDJQRVWLFFULWHULDDQGGLɣHUHQFHVLQ
study design. Previously, it was shown that there is extensive recombination in the 
ompA gene which could lead to contradicting observations on the relationship of the 
ompA genotypes to infection outcome (Harris et al. 2012). However, a recent study 
showed that genotype E, as the most epidemiologically successful genotype, has 
Table 9. The C. trachomatis ompA genotype distribution (%) in Finland 1987–2017.
Sero-/genotype 1987a
n=51
1996b
n=122
2008 
(I)c
n=144
2009–2011 (III)c
n=40
2010–2017 (IV)c
n=144
B 2 2 ND 5 ND
D 6 9 8 10 6
D/B ND 2 ND ND ND
E 25 33 40 40 47
ED 25 ND ND ND ND
Total 
(B-complex) 58 46 48 55 53
F 10 22 28 20 27
G 4 13 13 13 9
K 8 2 5 10 8
Total (Intermediate 
complex) 22 37 46 43 44
C 0 ND ND 0 ND
C/J ND 6 ND 0 ND
C-group ND 8 ND 0 ND
H 6 3 3 3 3
I 6 ND 0 0 1
J/Ja 8 ND 2 0 0
Total 
(C-complex) 20 17 5 3 4
a Micro-immunofluorescence (MIF) (Saikku & Wang 1987)
b C. trachomatis ompA PCR and restriction length polymorphism (RFLP) (Penttilä et al. 
1996)
c C. trachomatis ompA real-time PCR and genotype-specific probes (I, III, IV)
C-group: genotypes A, C, H, I, Ia, J, K and L3; ND, not determined
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HPHUJHGZRUOGZLGHUHODWLYHO\UHFHQWO\DQGKDVQRWEHHQDɣHFWHGE\UHFRPELQDWLRQ
in the ompA JHQH +DG¿HOG HW DO  2WKHU ELRORJLFDO FKDUDFWHULVWLFV RI 
C. trachomatis and host immunity have most probably more impact on the outcome 
of C. trachomatis infections than the ompA genotype alone.
In study II, the rectal specimens from both MSM and heterosexual women were 
LQFOXGHG7KHJHQRW\SHGLVWULEXWLRQLQWKHUHFWDOVDPSOHVDPRQJ060GLɣHUHG
from the proportion of genotypes in the rectal samples among women, and from 
the genotype distribution in the urogenital samples (study I) (Table 7). The four 
most common genotypes in rectal samples from MSM were G, D, E and L2. This 
genotype distribution is similar to that from other studies on MSM (Bax et al. 2011; 
Geisler et al. 2008; Isaksson et al. 2017). Among the rectal samples in women, 
JHQRW\SHV(DQG'ZHUHWKHPRVWIUHTXHQWO\GHWHFWHG7KLVFRUUHVSRQGVZHOOZLWK
an earlier study, where women were more often infected with genotype E and less 
often with genotype G than MSM at rectal sites (Geisler et al. 2008). It seems that 
the genotype distribution in the rectum samples among women is similar to that 
in the urogenital samples, but the proportion of genotypes in the rectal specimens 
DPRQJ060LVXQLTXHZLWKJHQRW\SH*SUHGRPLQDWLQJ7KHUHFWDOVSHFLPHQVIURP
heterosexual women tested more often positive for C. trachomatis (13%) than the 
rectal samples from MSM (7%). This highlights the importance of testing also women 
in addition to testing MSM at rectal sites. It has been shown that rectal infections 
among women are more common than the rate of reported anal intercourses (Chan 
et al. 2016). This could be due to inaccuracies in the self-reported history of sexual 
practices, but might also be explained by autoinoculation of C. trachomatis from 
WKHJDVWURLQWHVWLQDO WUDFW 5DQN	<HUXYD ,WPLJKWEHRIEHQH¿W WR WUHDW
ZRPHQZLWKGR[\F\FOLQHLQVWHDGRID]LWKURP\FLQDVGR[\F\FOLQHLVPRUHHɣHFWLYH
in clearing rectal C. trachomatis infections (Craig et al. 2015). LGV infections have 
rarely been reported in women (Peuchant et al. 2011; Verweij et al. 2012) and 
accordingly, only non-LGV genotypes were detected among women in study II. 
The pharyngeal specimens were from heterosexual men, MSM, and women. The 
JHQRW\SHGLVWULEXWLRQLQWKHSKDU\QJHDOVDPSOHVGLɣHUHGIURPWKHSURSRUWLRQRI
genotypes in the rectal samples among MSM. In the pharyngeal samples, the four 
PRVWFRPPRQJHQRW\SHVZHUH(')DQG*LQFRQWUDVWWRWKHPRVWIUHTXHQWO\
detected genotypes G, D, E and L2 in the rectal samples from MSM. The genotype 
distribution in the pharyngeal samples seems to be similar to that of the urogenital 
samples.
7KHGLɣHUHQFHV LQ WKH JHQRW\SHGLVWULEXWLRQV DW WKH UHFWDO SKDU\QJHDO DQG
XURJHQLWDO VLWHVFDQEHGXH WRPXOWLSOH UHDVRQV VXFKDVGLɣHUHQW WUDQVPLVVLRQ
dynamics, core-group associated factors or tissue tropism. It has been proposed that 
polymorphisms at certain loci are associated with rectal tropism of C. trachomatis 
VHURYDU*LVRODWHV-HɣUH\HWDO,WKDVDOVREHHQVSHFXODWHGWKDW/*9JHQRW\SHV
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PLJKWKDYHDKLJKHUDɤQLW\WRUHFWDOPXFRVDWKDQWRXUHWKUDOHSLWKHOLXPEXWWLVVXH
tropism of C. trachomatisKDVQRWEHHQFRQ¿UPHG,VDNVVRQHWDO9HUVWHHJ
et al. 2014). MSM and heterosexuals have their separate sexual networks which 
PRVWSUREDEO\OHDGWRGLɣHUHQWSURSRUWLRQVRIJHQRW\SHVDWWKHUHFWDOSKDU\QJHDO
and urogenital sites.
6.2 C. TRACHOMATIS LGV TYPES (II)
In study II, during the sample collection period between February 2009 and August 
2011 at HUSLAB, 8% of the rectal samples tested positive for C. trachomatis and 
13% of the genotyped samples contained LGV DNA. The C. trachomatis positivity in 
UHFWDOVDPSOHVZDVTXLWHVLPLODUWRWKHRQHUHSRUWHGLQWKH8.:DUGHWDO
In study II, LGV DNA was rarely (2%) detected in the pharyngeal samples. Of the 
QLQHSDWLHQWVZLWK/*9VL[ZHUHFRQ¿UPHGE\ompAVHTXHQFLQJWREHLQIHFWHGZLWK
genotype L2b and two with genotype L2. This corresponded well to the situation in 
other European countries where genotype L2b has been the causative genotype in 
WKHPDMRULW\RIFDVHVKRZHYHUDOVR/JHQRW\SHVKDYHEHHQLGHQWL¿HG6DYDJHHW
al. 2009). The proportion of infections due to genotypes L2b and L2 seems to be 
FKDQJLQJDVUHFHQWO\LQ6ZHGHQ/*9FDXVHGE\/ZDVGHWHFWHGPRUHIUHTXHQWO\
than before, half of the LGV cases being of genotype L2 in 2015 (Isaksson et al. 
2017). This information is unfortunately not available from Finland after 2011, as 
DVLPSOL¿HGYHUVLRQRIRXUJHQRW\SLQJPHWKRGWRGHWHFW/W\SHVZDVDGRSWHGLQ
DFOLQLFDO ODERUDWRU\,WGRHVQRWGLɣHUHQWLDWHWKH/W\SHVDQGWKH/*9SRVLWLYH
VDPSOHVDUHQRWURXWLQHO\VHTXHQFHGIRUompA.
2QO\RQH/*9SRVLWLYHSDWLHQWKDGVLJQL¿FDQWO\PSKDGHQRSDWK\ZKHUHDVWKH
other patients had a proctitis that was either fairly mild or asymptomatic. This 
was in contrast to a study performed in the UK, where the majority of rectal LGV 
infections were symptomatic (Ward et al. 2009). However, in more recent studies 
SHUIRUPHGLQWKH8.DQGWKH1HWKHUODQGVDSSUR[LPDWHO\DTXDUWHURIWKH/*9
infections were asymptomatic (de Vrieze et al. 2013; Saxon et al. 2016). In addition, 
inguinal LGV was rare compared to anal LGV in Amsterdam in 2005–2012 (de 
Vrieze et al. 2013). As reported before, the LGV positive patients in study II were 
all MSM, most of them had HIV and other STIs, and the patients were older (over 
35 years old) than patients with a urogenital infection (Savage et al. 2009). LGV 
was not detected in FVU or urethral samples among these LGV positive patients, 
and only one patient was positive for LGV both at the rectal and pharyngeal sites. 
Indeed, if MSM are tested at the urogenital sites only, approximately 14–85% 
of the infections will be missed depending on the study (Chan et al. 2016). The 
transmission patterns of LGV among MSM are not fully known. As very few cases 
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of urogenital LGV are reported (de Vrieze et al. 2017), it is proposed that rectum-
to-rectum transmission takes place through the use of shared sex toys, group sex, 
DQG¿VWLQJUHSRUWHGDPRQJ060GH9ULHV/*9WUDQVPLVVLRQPLJKWDOVR
occur through the ano-oral route via oral sex or the use of saliva as a lubricant for 
anal sex (de Vries 2016). After establishing LGV pharyngitis, C. trachomatis might 
pass through the gastrointestinal tract to the rectum and be transmitted further. 
,QVWXG\,,DOWRJHWKHUQLQH/*9SRVLWLYHSDWLHQWVZHUHLGHQWL¿HGWKUHHSDWLHQWV
in 2009, two patients in 2010 and four patients in 2011. It is not known whether the 
¿UVW/*9FDVHDPRQJ060HPHUJHGLQ)LQODQGLQRUHDUOLHU7KH¿UVWWZR/*9
cases in Sweden were reported in 2004 (Berglund et al. 2005), and retrospective 
analysis carried out in Sweden revealed no additional cases of LGV in 2004–2005 
(Klint et al. 2006). We were unfortunately unable to perform a retrospective analysis 
of rectal samples in Finland. It has been shown that the L2b type causing the 
LGV outbreak in Europe was already present in San Francisco, USA in the 1980s 
and was circulating in Amsterdam in 2000 without being detected (Spaargaren, 
Schachter, et al. 2005). 
Since 2011, after introducing an in-house typing test (II) for the C. trachomatis 
1$$7SRVLWLYHVSHFLPHQV LQWRDFOLQLFDO ODERUDWRU\ ODERUDWRU\FRQ¿UPHG/*9
LQIHFWLRQVKDYHEHHQQRWL¿HGE\FOLQLFLDQVWRWKH1,'5%\WKHHQGRI\HDU
/*9FDVHVZHUHUHSRUWHGWRWKH1,'5RIZKLFKRQHWKLUGZDVUHSRUWHGLQ
1,'52I WKH/*9 LQIHFWLRQVPRVWZHUH UHSRUWHGDPRQJ060
ZHUHDFTXLUHGLQ)LQODQGZHUHDFTXLUHGLQDQRWKHUFRXQWU\LQ(XURSHDQGIRU
13 cases the information was not available. The nationality of the LGV patients 
was Finnish in 39 cases and non-Finnish in 12 cases. Most of the Finnish LGV 
cases are probably sporadic imports from other European countries. In contrast 
WRWKHUDWKHUORZQXPEHURIQRWL¿HG/*9FDVHVLQ)LQODQGDOPRVWFDVHVRI
LGV were reported in 24 European countries in 2017 (ECDC 2019b). France, the 
1HWKHUODQGV6SDLQDQGWKH8QLWHG.LQJGRPDFFRXQWHGIRURIDOOQRWL¿HG/*9
cases and in these countries endemic LGV infections occur. As in Finland, almost 
all cases were reported among MSM and 64% of the patients were HIV positive. 
The number of reported LGV cases in 2017 decreased by 13 % compared to 2016, 
ZKLFKZDVWKH¿UVWUHGXFWLRQLQWKHQXPEHURIFDVHVVLQFH7KLVUHGXFWLRQLV
possibly linked to changes in testing practices rather than the decreased transmission 
of LGV. Overall, the number of LGV cases reported is likely an underestimation 
EHFDXVHPDQ\FRXQWULHVLQ(XURSHGRQRWKDYHVSHFL¿FGLDJQRVWLFWHVWVRUDQDWLRQDO
surveillance system for LGV. 
Urogenital C. trachomatisLQIHFWLRQVDUHGLDJQRVHGZLWKVHQVLWLYHDQGVSHFL¿F
1$$7VEXWFRPPHUFLDO3&5EDVHGWHVWVYDOLGDWHGIRUWKHGHWHFWLRQRI/*9IURP
rectal samples are still unavailable. As LGV infections have previously been rare 
in the Western countries, they could have been misdiagnosed as, for example, 
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LQÀDPPDWRU\ERZHOGLVHDVH*DOOHJRVHWDORUO\PSKRPD&ULFN[HWDO
7KHODFNRIVSHFL¿FWHVWVFRPELQHGZLWKXQDZDUHQHVVRIWKHGLVHDVHFDQOHDGWR
GHOD\HGGLDJQRVLVLQDGHTXDWHDQWLELRWLFWUHDWPHQWDQGIXUWKHUWUDQVPLVVLRQRIWKH
infection. Since 2011, it has been possible to test clinical specimens for LGV at 
+86/$%+HOVLQNLDVDQDWLRQDOVHUYLFHZLWKWKHLQKRXVH3&5PHWKRGVHWXSLQ
study II upon suspicion of an LGV infection.
6.3 C. TRACHOMATIS VARIANTS (I)
Despite our proximity to Sweden, the new variant was rarely detected in Finland, 
as only two samples (0.4%) contained the nvCT in study I. Unfortunately, both 
patients were lost from the follow-up, so we were not able to obtain information 
on the possible travel history or contacts to Sweden. Except for Norway, where the 
nvCT comprised approximately 3% of the C. trachomatis cases detected by a Becton 
Dickinson test in 2008, the nvCT has seldom been reported or has been reported 
absent in several countries outside Sweden (Dahlberg et al. 2018). The population 
DɣHFWHGE\WKHQY&7FRPSULVHGPDLQO\RI\RXQJKHWHURVH[XDO LQGLYLGXDOVZLWK
localised sexual networks in Sweden, which may be the reason why the nvCT did 
QRWVSUHDGVLJQL¿FDQWO\RXWVLGH6ZHGHQ
$IWHU WKH LGHQWL¿FDWLRQRI WKHQY&7DQG WKHUHOHDVHRI WKHXSGDWHG1$$7V
WKHSURSRUWLRQRILQIHFWLRQVFDXVHGE\WKHQY&7GHFUHDVHGVLJQL¿FDQWO\LQ6ZHGHQ
'DKOEHUJHWDO,QWKHFRXQWLHVXVLQJWKH5RFKHWHVWXQDEOHWRGHWHFWWKH
nvCT, the decrease was from 56% in 2007 to 7% in 2015, and in the counties 
using the Becton Dickinson test capable of detecting the nvCT, the decrease was 
from 19% in 2007 to 5% in 2015. The rates of PID and ectopic pregnancy were 
KLJKHULQWKHFRXQWLHVXVLQJWKHWHVWXQDEOHWRGHWHFWWKHQY&7EXWWKLVHɣHFWZDV
marginal at the national level in Sweden. The emergence of the nvCT seemed to 
be clonal, as all of the nvCT strains were of genotype E, and a subset of the nvCT 
strains analysed had identical ompA genes and was identical in an MLST analysis 
(Dahlberg et al. 2018). The nvCT did not appear to have an enhanced biological 
¿WQHVVin vitro, and the rapid spread in Sweden was probably due to the strong 
diagnostic selective advantage (Unemo et al. 2010). Indeed, a recent study based 
on a mathematical model proposed that the nvCT was 5% less transmissible than 
the wild type of C. trachomatis, and a 17% reduction in the duration of infection 
for the nvCT compared to the wild type of C. trachomatis was observed (Smid et 
al. 2019). Future investigations on the FI-nvCT, initially detected in early 2019, 
PLJKWUHYHDOZKHWKHUWKLVYDULDQWKDVDQDOWHUHG¿WQHVVRUDGLɣHUHQWRXWFRPHRI
infection compared to the wild type, or if the missed cases due to the variant had 
DQHɣHFWRQWKHUDWHVRIC. trachomatisDVVRFLDWHGVHTXHODH
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The genomic mutations observed with the Swedish nvCT and the FI-nvCT are a 
QDWXUDOFRQVHTXHQFHRIWKHPLFURELDOHYROXWLRQFRPELQHGZLWKWKHKLJKGLDJQRVWLF
selective pressure on C. trachomatis. This might be seen as an alternative strategy 
for C. trachomatis to spread, as antibiotic resistance among C. trachomatis strains 
has remained rare. Detecting new variants of C. trachomatis represents a challenge 
for laboratories as these bacteria are being detected mostly by NAATs. Laboratories 
should monitor the incidence and positivity rates of C. trachomatis and participate 
LQH[WHUQDOTXDOLW\DVVHVVPHQWSURJUDPPHV7KHXVHRIGXDOWDUJHW1$$7VDQGEDFN
up NAATs for C. trachomatis should be considered in laboratories. At a national 
OHYHOLWFRXOGEHRIEHQH¿WLIGLɣHUHQW1$$7VDUHXVHGLQGHWHFWLQJC. trachomatis 
infections. If there is suspicion of failure of detection, specimens can be sent to 
DQRWKHUODERUDWRU\IRUFRQ¿UPDWRU\WHVWLQJZLWKDQRWKHU1$$7,QDGGLWLRQWRWKH
actions performed by the laboratories, the European Commission has regulations 
for the medical devices and in vitro GLDJQRVWLFPHGLFDO GHYLFHV UHTXLULQJ WKH
manufacturers to perform post-market monitoring of the diagnostic tests. This 
could prevent the variants from spreading unnoticed. 
6.4 PREVALENCE OF HSV, HHV-6, HPV AND  
 M. GENITALIUM (IV)
Among the urogenital samples of young women participating in a C. trachomatis 
VFUHHQLQJWULDOLQVWXG\,9+39'1$ZDVVLJQL¿FDQWO\PRUHIUHTXHQWO\GHWHFWHG
among the C. trachomatis positives than the negatives (66% vs. 25%). This suggests 
greater sexual activity and exposure to sexually transmissible microbes among these 
LQGLYLGXDOV6LPLODUO\ LQDQ,WDOLDQVWXG\+39FRLQIHFWLRQZDVIUHTXHQW
among C. trachomatis infected women and the prevalence of HPV was even higher 
DPRQJ\HDUROGZRPHQ6HUDFHQLHWDO7KLVLVRILPSRUWDQFHDVC. 
trachomatis might be a co-factor in the development of cervical cancer (Castellsagué 
et al. 2014; Lehtinen et al. 2011). Globally, there is a relationship between HPV 
prevalence and age, as the highest rates are observed in women younger than 25 
years with a decline in older age groups (Forman et al. 2012). The prevalence of 
HPV among young women is over 20% in Europe and North America (Forman 
et al. 2012). 
The prevalence of HSV, HHV-6 and M. genitaliumZDVQRWVLJQL¿FDQWO\GLɣHUHQW
among the C. trachomatis positive and negative young women. HSV DNA was 
UDUHO\GHWHFWHGLQWKHXURJHQLWDOVDPSOHVRI\RXQJZRPHQ7KLV¿QGLQJLV
in agreement with the previous Finnish data, as a prevalence of 3% of clinically 
diagnosed HSV cases was reported in women at twelve outpatient clinics in 1995–
2006 (Hiltunen-Back et al. 2009), and approximately 2% of the clients at an STI 
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clinic were HSV culture positive in 1994–2012 (Kortekangas-Savolainen et al. 2014; 
Kortekangas-Savolainen & Vuorinen 2007). The seroprevalence for HSV-1 was 45% 
and for HSV-2 11% among pregnant Finnish women in 2012 (Puhakka et al. 2016). 
The global prevalence estimate for genital HSV infections was 0.8% (15–19 year 
olds) and 2% (20–24 year olds) for HSV1, and 4.6% (15–19 year olds) and 7.8% 
(20–24 year olds) for HSV2 (Looker, Magaret, May, et al. 2015; Looker, Magaret, 
Turner, et al. 2015). HHV-6 DNA was detected in 12% of the samples analysed. 
Similarly, an HHV-6 prevalence of up to 10% was shown in the vaginal secretions 
of non-pregnant women in the USA (Leach et al. 1994), whereas a prevalence of up 
to 26% was reported in the genital tract specimens of pregnant Japanese women 
(Maeda et al. 1997). HHV-6 DNA positivity among the women can be explained 
by reactivation or (re)infection of HHV-6, as this virus induces a lifelong latent 
infection in humans.
The global estimate for the prevalence of M. genitalium was 1.7% in under 
25-year-old women (Baumann et al. 2018), which is slightly lower than the global 
prevalence of 3.8% for C. trachomatis LQ±\HDUROGZRPHQ5RZOH\HWDO
2019). The prevalence of M. genitalium DNA was 3.2% among samples of young 
Finnish women participating in a C. trachomatis screening trial. Earlier, a somewhat 
higher prevalence of 5.6% for M. genitalium was reported among clients at an STI 
clinic in Finland (Hokynar et al. 2018). In the other Nordic countries, the prevalence 
of M. genitalium was 9.8% in Sweden, 4.9% in Norway and 9.0% in Denmark 
(Unemo et al. 2018). In Norway, the prevalence of M. genitalium is suggested to be 
ORZHUGXHWRHQKDQFHGWHVWLQJWUHDWPHQWDQGSDUWQHUQRWL¿FDWLRQ7KHVDPSOHVLQ
study IV were collected from women volunteering in an HPV vaccination trial and 
simultaneously in a C. trachomatis screening trial, and the sexual activity among the 
participants may have been higher. Due to this, the true population-based prevalence 
of HPV, HSV, HHV-6 and M. genitalium and the prevalence of C. trachomatis and 
HPV co-infection might be lower than the ones reported here.
In study IV, we detected two samples with a macrolide resistant M. genitalium 
among the ten samples positive for M. genitalium. Previously, mutations leading 
to macrolide resistance were detected in 31% of M. genitalium positive samples 
among clients at an STI clinic in Finland (Hokynar et al. 2018). In the other Nordic 
countries, the prevalence of M. genitalium macrolide resistance was 18% in Sweden, 
LQ1RUZD\DQGLQ'HQPDUN8QHPRHWDO7KLVUHÀHFWVGLɣHUHQFHV
in the national treatment guidelines, as doxycycline is recommended in Sweden 
and azithromycin in Norway and Denmark in the treatment of C. trachomatis 
LQIHFWLRQV)OXRURTXLQRORQHUHVLVWDQFHLQM. genitalium has been demonstrated to 
be extremely rare in Finland (Hokynar et al. 2018), hence it was not investigated 
here. N. gonorrhoeae was rarely detected in the samples collected from young 
women. Previously, a prevalence of 0.3% was reported for N. gonorrhoeae among 
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clients at an STI clinic in Finland (Hokynar et al. 2018). The global prevalence of 
N. gonorrhoeaeZDVLQZRPHQ±\HDUVRIDJH LQ5RZOH\HWDO
&5%ZHUHUDUHO\GHWHFWHGDPRQJWKHXURJHQLWDOVDPSOHV
The prevalence of HSV, HHV-6, HPV and M. genitaliumGLGQRWVLJQL¿FDQWO\
GLɣHUEHWZHHQWKRVHZKRFOHDUHGWKHC. trachomatis infection and those who did not. 
HHV-6 DNA was slightly more numerous among those who gave a C. trachomatis 
SRVLWLYH72&VDPSOHWKDQDQHJDWLYH72&VDPSOHYVEXWWKLVGLɣHUHQFH
ZDVQRWVWDWLVWLFDOO\VLJQL¿FDQW(DUOLHUVWXGLHVKDYHUHSRUWHGLQWHUHVWLQJLQWHUDFWLRQV
between HHV-6 and C. trachomatis. HHV-6 induced persistence of C. trachomatis 
(Prusty et al. 2012) and C. trachomatis activated replication of latent HHV-6 (Prusty 
et al. 2013). Similarly, a study on another herpesvirus showed that a C. trachomatis 
and HSV co-infection drives C. trachomatis persistence in vitro (Deka et al. 2006). 
This might be of importance as persistent forms of C. trachomatis are more resistant 
to azithromycin (Wyrick & Knight 2004). As 13% of the TOC samples were positive 
for C. trachomatisWKHHɣHFWRIFRLQIHFWLRQVHVSHFLDOO\WKRVHGXHWRKHUSHVYLUXVHV
warrants further studies. 
The ompA genotype distribution of C. trachomatis was similar among those 
who cleared the infection and those who did not. The relation of genotype to the 
clearance of uncomplicated genital C. trachomatis has been investigated, but the 
results in these few studies have been inconclusive (Geisler 2010). This suggests 
that genotype may not have a major part in the resolution of infection. Multiple 
factors, including other biological characteristics of C. trachomatis, host immunity 
(Batteiger, Xu, et al. 2010) and infectious load (Walker et al. 2012) probably play 
a role in clearance.
Co-infections with C. trachomatis, M. genitalium, HSV, HHV-6 and HPV can 
KDYHVHYHUDOLQWHUDFWLRQVDQGFRQVHTXHQFHVRQWKHRXWFRPHRILQIHFWLRQEXWWKHVH
LQWHUDFWLRQVDUHRQO\SDUWLDOO\GH¿QHG7KH LQIRUPDWLRQRQWKH ORFDODQGJOREDO
epidemiology of these sexually transmitted pathogens is important in infection 
control when infection management guidelines are developed. Study IV showed the 
high prevalence of a C. trachomatis and HPV co-infection among young women 
ZKLFKFRXOGKDYHSDWKRORJLFDOFRQVHTXHQFHVLQWKHFHUYL[,QDGGLWLRQVWXG\,9
explored the prevalence rates of HSV and HHV-6 DNA in urogenital specimens 
DPRQJ\RXQJZRPHQIRUWKH¿UVWWLPHLQ)LQODQG7KLVLQIRUPDWLRQKDVUHOHYDQFH
as previous studies have shown that both these pathogens can induce C. trachomatis 
persistence, which could hamper antibiotic treatment of infections. The overall 
prevalence rates of HSV, HHV-6, HPV and M. genitalium were similar to those 
reported elsewhere. 
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6.5 C. TRACHOMATIS GROWTH DYNAMICS AND  
 GENE EXPRESSION (III)
The expression of the C. trachomatis ompA, cpaf, tarp and tox genes was investigated 
in vivoLQFHUYLFDOVZDEVZLWKUHDOWLPH573&5EDVHGDQDO\VHVLQVWXG\,,,P51$
of the ompA, cpaf, tarp and toxJHQHVZDVLQIUHTXHQWO\GHWHFWHGLQFHUYLFDOVZDEV
7KH¿YHDQDO\VHGC. trachomatis low-passage-number clinical isolates expressed 
these genes in in vitroLQIHFWLRQV7KLVVXJJHVWVWKDWWKHGLɣHUHQFHVDUHOLNHO\WREH
GXHWRWKHVPDOODPRXQWRIFKODP\GLDOP51$LQWKHFHUYLFDOVZDEVDQGQRWGXHWR
WKHGLɣHUHQFHVEHWZHHQLVRODWHV7KLVZDVDOVRVXSSRUWHGE\VHURORJ\DVDQWLERGLHV
against the proteins encoded by genes ompA, cpaf, tarp and tox were detected in sera 
from the C. trachomatis positive patients (our unpublished observation). The few 
earlier studies on the in vivo gene expression of C. trachomatis analysed cytobrush 
cervical samples (Jha et al. 2009) or synovial biopsies (Gerard et al. 2013) which 
probably contain more C. trachomatis cells than swab specimens. The use of cervical 
biopsies may have resulted in a larger number of positive samples in the real-time 
3&5DVVD\VEXWWKLVLQYDVLYHVDPSOHW\SHLVFOHDUO\PXFKPRUHGLɤFXOWWRREWDLQ
The growth kinetics of the C. trachomatis reference strains and clinical isolates 
were analysed with the ompA3&5$OOFOLQLFDOLVRODWHVH[FHSWRQH(H[KLELWHG
a slower growth rate than the reference strains. The reference strains and the 
clinical isolate E127 showed a doubling time of approximately two to three hours 
and the rest of the clinical isolates a doubling time of approximately four hours. 
Similarly, a generation or doubling time of two to three hours has been estimated 
for urogenital C. trachomatis reference strains (Borges et al. 2010; Miyairi et al. 
,QDGGLWLRQWKHUHIHUHQFHVWUDLQVLQVWXG\,,,ZHUHPRUHHɤFLHQWLQSURGXFLQJ
progeny than the clinical isolates. C. trachomatis reference strains are most probably 
adapted to HeLa229 cells and the in vitro growth conditions in contrast to the low-
passage-number isolates cultured from clinical samples, which has been shown 
before (Borges et al. 2015; Nunes et al. 2007). In this study, the growth properties 
of the low-passage-number clinical isolate E127 resembled those of the reference 
strains. This isolate was cultured from a cervical sample of an asymptomatic 
C. trachomatis seronegative woman, whose partner was positive for C. trachomatis. 
%DVHGRQ WKLVFOLQLFDOGDWDDYDLODEOH VKHPD\KDYHEHHQH[SHULHQFLQJKHU¿UVW 
C. trachomatis infection, but the ultimate factors explaining the faster growth rate 
RIWKLVFOLQLFDOLVRODWHUHPDLQXQGH¿QHG7KHRWKHUFOLQLFDOLVRODWHVDQDO\VHGZHUH
from C. trachomatis seropositive women possibly having repeated C. trachomatis 
infections.
In study III, the in vitro expression of the cpaf, tarp and toxJHQHVXVLQJ¿YH
clinical low-passage-number isolates and reference strains type E and F was analysed 
ZLWKUHDOWLPH573&5EDVHGDQDO\VHVLQ+H/DFHOOVIRUWKH¿UVWWLPHDWGLɣHUHQW
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stages of the chlamydial developmental cycle. Dissimilarities were observed in the 
C. trachomatisJHQHH[SUHVVLRQSUR¿OHEHWZHHQWKHFOLQLFDOLVRODWHVDQGWKHUHIHUHQFH
strains. The expression of cpaf was high in the reference strains compared to the 
clinical isolates in the mid-phase (12–24 hpi) of the developmental cycle. The 
UHOHYDQFHRIWKLVLVQRWNQRZQDVWKHSUHYLRXVO\LGHQWL¿HGWDUJHWPROHFXOHVDQG
HɣHFWVRI&3$)GXULQJDFKODP\GLDOLQIHFWLRQKDYHEHHQTXHVWLRQHG&KHQHWDO
2012). The expression of tox occurred earlier (at 12 hpi vs. at 24 hpi) in the reference 
strains and the clinical isolate E127 than in the other clinical isolates. Chlamydial 
cytotoxin has a role early in the entry phase of the developmental cycle (Belland et 
al. 2001), so this might also be associated with the faster growth of these strains. 
Only the expression of tarp was fairly similar in the clinical isolates and the reference 
strains. In study III, the peak of expression for tarp was observed later than for the 
other genes in the clinical isolates and the reference strains. Similarly, in earlier 
studies, tarp expression was categorised as late (24–36 hpi) for type L2 (Nicholson 
et al. 2003), or tarp was expressed at 8–40 hpi in type D (Belland et al. 2003).
The expression of ompA in the clinical isolates and reference strains peaked in 
the middle of the chlamydial developmental cycle at 24 hpi. This correlates with the 
need for MOMP as an important structural component of the outer membrane in 
GLYLGLQJ5%VIRUPLQJQHZRUJDQLVPV&DOGZHOOHWDO7KHH[SUHVVLRQRIompA 
occurred earlier in the reference strains and in the clinical isolate E127 than in the 
other clinical isolates. The expression of ompA in this study was similar to that in 
the previous studies (Belland et al. 2003; Gomes et al. 2005; Nunes et al. 2007), 
which suggests that the infection model used in study III is comparable to those 
XVHGEHIRUH7KHGLVVLPLODULWLHVLQJHQHH[SUHVVLRQSUR¿OHVEHWZHHQGLɣHUHQWFOLQLFDO
isolates are probably due to the intrinsic properties of the single isolates, because the 
growth conditions were identical. Some of the comparisons of gene expression have 
EHHQPDGHWRSUHYLRXVVWXGLHVXWLOLVLQJPLFURDUUD\RU51$VHTXHQFLQJWHFKQLTXHV
+RZHYHULWKDVEHHQVKRZQWKDWWKH573&5GDWDFRUUHODWHZHOOZLWKWKHPLFURDUUD\
DQG51$VHTXHQFLQJGDWD%HOODQGHWDO)HUUHLUDHWDO1LFKROVRQHW
al. 2003). 
Studying C. trachomatis gene expression and growth kinetics during in vitro and 
in vivo infections is essential in understanding disease pathogenesis and evaluating 
WKHHɣHFWVWKDWLPPXQHPHGLDWRUVRUDQWLPLFURELDOVKDYHRQWKHC. trachomatis 
infection. Study III showed that the selection of the C. trachomatis strains for 
gene expression experiments can have an impact on the results, as clinical isolates 
DFWHGGLɣHUHQWO\FRPSDUHGWRUHIHUHQFHVWUDLQV7KHXVHRIFDUHIXOO\FKDUDFWHULVHG
low-passage-number C. trachomatis isolates instead of reference strains in gene 
H[SUHVVLRQVWXGLHVPLJKWEHWWHUUHÀHFWWKHVLWXDWLRQin vivo.
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7. CONCLUSIONS AND FUTURE PROSPECTS
The intracellular bacterium, C. trachomatis, is a master in playing hide and seek. 
This was demonstrated with the re-emergence of an old disease, lymphogranuloma 
venereum, with a new often asymptomatic manifestation of the infection. In 
addition, the accumulation of deletions and mutations in the bacterial genome, 
LQFOXGLQJWKHWDUJHWVHTXHQFHVRIGLDJQRVWLF1$$7VOHDGLQJWRIDLOLQJGHWHFWLRQ
has been witnessed twice with C. trachomatis. Causing asymptomatic infections 
and evading detection seem to be a survival strategy of C. trachomatis, enabling it 
to continue spreading unnoticed.
Typing of C. trachomatis remains important in epidemiological surveillance, 
revealing transmission networks and distinguishing reinfection from treatment 
IDLOXUH,QWKHIXWXUHKLJKUHVROXWLRQJHQRW\SLQJWHFKQLTXHVVXFKDV0/67DQG
WGS will prove useful, especially in situations where a single genotype dominates 
in a population. Distinguishing LGV types from non-LGV types is important in 
WKHSURSHUPDQDJHPHQWRIUHFWDO LQIHFWLRQVDV/*9LQIHFWLRQVUHTXLUHD ORQJHU
antibiotic treatment regimen compared to the treatment of urogenital infections. 
7KLVWKHVLVVKRZHGIRUWKH¿UVWWLPHVLQFHWKHVWKDW/*9LQIHFWLRQVDOVRRFFXULQ
Finland among MSM, a group vulnerable to multiple sexually transmitted infections. 
'HWHFWLRQRI/*9LVVWLOOEDVHGRQLQKRXVH3&5WHVWVZKLFKDUHQRWDYDLODEOHLQDOO
SDUWVRIWKHZRUOGOHDGLQJWRXQGLDJQRVHG/*9LQIHFWLRQV,QDGGLWLRQWR/*9VSHFL¿F
tests, commercial screening tests validated for the analysis of extragenital samples 
are needed, as C. trachomatis rectal infections are prevalent also among women 
in Finland and elsewhere. The evolution of C. trachomatis genomes seems to be 
DQRQJRLQJSURFHVVDQGFDQVHULRXVO\DɣHFWWKHODERUDWRU\GLDJQRVLVRILQIHFWLRQV
In this thesis however, the Swedish variant of C. trachomatis was rarely detected 
in Finland. Clinical laboratories should be aware of the ability of C. trachomatis to 
develop mutations which can lead to failing detection of infections.
7KHLQWHUDFWLRQVDQGFRQVHTXHQFHVRIC. trachomatis co-infections with other 
sexually transmitted pathogens are numerous, but remain an understudied area of 
research. It is important to understand the local and global prevalence of sexually 
transmitted microbes in the management of infections. This thesis showed that 
C. trachomatis co-infections with HPV are extremely prevalent among young 
women in Finland. This warrants further studies as the co-infection of these 
DJHQWVLVDSUHUHTXLVLWHIRUFHUYLFDOFDQFHU7KLVWKHVLVUHYHDOHGGLVVLPLODULWLHVLQ
the transcriptional gene expression patterns between low-passage-number clinical 
C. trachomatis isolates and reference strains, which suggests that the use of clinical 
LVRODWHVPLJKWEHWWHUUHÀHFWWKHVLWXDWLRQGXULQJKXPDQLQIHFWLRQ,QWKHIXWXUH 
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C. trachomatis gene expression studies will most probably be focused on the analysis 
of whole transcriptomes. In addition, the analysis of the in vivo gene expression of 
C. trachomatisZLOOEHQH¿WIURPWKHGHYHORSPHQWRIPRUHVHQVLWLYHWUDQVFULSWRPH
DQDO\VLVPHWKRGVVXFKDVVLQJOHFHOO51$VHTXHQFLQJ
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